

Preparation of 1,6-Disubstituted Azabenzimidazoles as Kinase Inhibitors

An important large family of enzymes is the protein kinase enzyme family. Currently, there are about 500 different known protein kinases. Protein kinases serve to catalyze the phosphorylation of an amino acid side chain in various proteins by the transfer of the γ -phosphate of the ATP-Mg²⁺ complex to said amino acid side chain. These enzymes control the majority of the signaling processes inside cells, thereby governing cell function, growth, differentiation and destruction (apoptosis) through reversible phosphorylation of the hydroxyl groups of serine, threonine and tyrosine residues in proteins. Studies have shown that protein kinases are key regulators of many cell functions, including signal transduction, transcriptional regulation, cell motility, and cell division. Several oncogenes have also been shown to encode protein kinases, suggesting that kinases play a role in oncogenesis. These processes are highly regulated, often by complex intermeshed pathways where each kinase will itself be regulated by one or more kinases. Consequently, aberrant or inappropriate protein kinase activity can contribute to the rise of disease states associated with such aberrant kinase activity. Due to their physiological relevance, variety and ubiquitousness, protein kinases have become one of the most important and widely studied family of enzymes in biochemical and medical research.

The protein kinase family of enzymes is typically classified into two main subfamilies: Protein Tyrosine Kinases and Protein Serine/Threonine Kinases, based on the amino acid residue they phosphorylate. The serine/threonine kinases (PSTK), includes cyclic AMP- and cyclic GMP-dependent protein kinases, calcium- and phospholipid-dependent protein kinase, calcium- and calmodulin-dependent protein kinases, casein kinases, cell division cycle protein kinases and others. These kinases are usually cytoplasmic or associated with the particulate fractions of cells, possibly by anchoring proteins. Aberrant protein serine/threonine kinase activity has been implicated or is suspected in a number of pathologies such as rheumatoid arthritis, psoriasis, septic shock, bone loss, many cancers and other proliferative diseases. Accordingly, serine/threonine kinases and the signal transduction pathways which they are part of are important targets for drug design. The tyrosine kinases phosphorylate tyrosine residues. Tyrosine kinases play an equally important role in

cell regulation. These kinases include several receptors for molecules such as growth factors and hormones, including epidermal growth factor receptor, insulin receptor, platelet derived growth factor receptor and others. Studies have indicated that many tyrosine kinases are transmembrane proteins with their receptor domains located on the outside of the cell and their kinase domains on the inside. Much work is also
5 under progress to identify modulators of tyrosine kinases as well.

A major signal transduction systems utilized by cells is the RhoA- signalling pathways. RhoA is a small GTP binding protein that can be activated by several extracellular stimuli such as growth factor, hormones, mechanic stress, osmotic
10 change as well as high concentration of metabolite like glucose. RhoA activation involves GTP binding, conformation alteration, post-translational modification (geranylgeranyllization and farnesylation) and activation of its intrinsic GTPase activity. Activated RhoA is capable of interacting with several effector proteins including ROCKs (ROCK1 and ROCK2, also referred to below as 'ROCK' or
15 'ROCKs') and transmit signals into cellular cytoplasm and nucleus.


ROCK1 and 2 constitute a family of kinases that can be activated by RhoA-GTP complex via physical association. Activated ROCKs phosphorylate a number of substrates and play important roles in pivotal cellular functions. The substrates for ROCKs include myosin binding subunit of myosin light chain phosphatase (MBS, also named MYPT1), adducin, moesin, myosin light chain (MLC), LIM kinase as
20 well as transcription factor FHL. The phosphorylation of theses substrates modulate the biological activity of the proteins and thus provide a means to alter cell's response to external stimuli. One well documented example is the participation of ROCK in smooth muscle contraction. Upon stimulation by phenylephrine, smooth muscle from
25 blood vessels contracts. Studies have shown that phenylephrine stimulates b-adrenergic receptors and leads to the activation of RhoA. Activated RhoA in turn stimulates kinase activity of ROCK1 and which in turn phosphorylates MBS. Such phosphorylation inhibits the enzyme activity of myosin light chain phosphatase and increases the phosphorylation of myosin light chain itself by a calcium-dependent
30 myosin light chain kinase (MLCK) and consequently increases the contractility of myosin-actin bundle, leading to smooth muscle contraction. This phenomena is also sometimes called calcium sensitization. In addition to smooth muscle contraction,

ROCKs have also been shown to be involved in cellular functions including apoptosis, cell migration, transcriptional activation, fibrosis, cytokinesis, inflammation and cell proliferation. Moreover, in neurons ROCK plays a critical role in the inhibition of axonal growth by myelin-associated inhibitory factors such as myelin-associated glycoprotein (MAG). ROCK-activity also mediates the collapse of growth cones in developing neurons. Both processes are thought to be mediated by ROCK-induced phosphorylation of substrates such as LIM kinase and myosin light chain phosphatase, resulting in increased contractility of the neuronal actin-myosin system.

The present inventors have discovered novel azabenzimidazole compounds, which are inhibitors of ROCK activity and show interesting selectivity over other protein kinases. Such derivatives are useful in the treatment of disorders associated with inappropriate ROCK activity.

DETAILED DESCRIPTION OF THE INVENTION

The present invention thus provides compounds of the general formula (I)



(I)

and physiologically acceptable salts wherein,

X represents C₁₋₆ alkyl, NR³, O or S(O)_n where n is 0, 1, or 2;

R¹ represents C₁₋₆ alkyl, optionally substituted by a group selected from the group consisting of optionally substituted phenyl, C₁₋₃ alkoxy, C₃₋₇cycloalkyl, heteroaryl, heterocyclyl, NH₂, R⁴R⁵N, acylamino, hydroxy, CONR⁴R⁵, NR⁴COR⁵, SO₂NR⁴R⁵, NR⁴SO₂R⁵, OalkNR⁴R⁵, or SalkNR⁴R⁵, alkenyl optionally substituted phenyl, heterocyclyl, or heteroaryl, optionally substituted phenyl, heteroaryl, cycloalkyl, cycloalkylalkyl, heterocyclyl;

R² represents C₁₋₆ alkyl, optionally substituted by a group selected from the group consisting of optionally substituted phenyl, C₃₋₇cycloalkyl, heteroaryl, heterocyclyl,

NH₂, R⁴R⁵N, acylamino, hydroxy, CO₂R⁴, CONR⁴R⁵, NR⁴COR⁵, NR⁴CSR⁵, SO₂NR⁴R⁵, NR⁴SO₂R⁵, OalkNR⁴R⁵, optionally substituted phenyl, heteroaryl, heterocyclyl, CONR⁴R⁵;

R³ represents hydrogen, C₁₋₆ alkyl, and C₃₋₇ cycloalkyl or R³ and R² together form a

5 ring;

R⁴ and R⁵ independently represent a group selected from hydrogen, C₁₋₆ alkyl, C₃₋₇ cycloalkyl, C₃₋₇ cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl or heterocyclylalkyl;


Alk is a C₂₋₄ straight or branched alkylene chain;

10 and the group X-R² can represent F, Cl, or Br.

It will be appreciated that any of the substituents R¹ to R⁵ as defined in formula (1) above may contain at least one asymmetric center and it is to be understood that the invention includes all possible enantiomers arising therefrom and mixtures thereof including racemates.

15

The present invention thus provides compounds of the general formula (I)



(I)

and physiologically acceptable salts wherein,

X is O or S;

20 R¹ represents C₁₋₄ alkyl, optionally substituted phenyl, heteroaryl, C₃₋₆cycloalkyl, C₃₋₆cycloalkylalkyl;

R² represents C₁₋₃ alkyl, optionally substituted by a group selected from the group consisting of optionally substituted phenyl, C₁₋₃ alkoxy C₃₋₇cycloalkyl, heteroaryl, heterocyclyl, NH₂, R⁴R⁵N, acylamino, hydroxy, CO₂R⁴, CONR⁴R⁵, NR⁴COR⁵,

25 SO₂NR⁴R⁵, NR⁴SO₂R⁵ optionally substituted phenyl, heteroaryl, heterocyclyl, CONR⁴R⁵;


R^4 and R^5 , independently, represent a group selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl, heterocyclyl and heterocyclylalkyl, or R^4 and R^5 together form a ring;
Alk is a C_{2-4} straight or branched alkylene chain.

5

It will be appreciated that any of the substituents R^1 to R^5 as defined in formula (1) above may contain at least one asymmetric center and it is to be understood that the invention includes all possible enantiomers arising therefrom and mixtures thereof including racemates.

10

The present invention thus provides compounds of the general formula (I)



(I)

and physiologically acceptable salts wherein,

X is O;

- 15 R^1 represents C_{1-4} alkyl, optionally substituted phenyl, heteroaryl, heterocyclyl, C_{1-3} alkoxy, C_{3-6} cycloalkyl, C_{3-6} cycloalkylalkyl;
 R^2 represents optionally substituted phenyl, heteroaryl, heterocyclyl, $CONR^4R^5$;
 R^4 and R^5 , independently, represent a group selected from hydrogen, C_{1-6} alkyl, C_{3-7} cycloalkyl, C_{3-7} cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroarylalkyl,
 20 heterocyclyl and heterocyclylalkyl, or R^4 and R^5 together form a ring;
 Alk is a C_{2-4} straight or branched alkylene chain.

- It will be appreciated that any of the substituents R^1 to R^5 as defined in formula (1) above may contain at least one asymmetric center and it is to be understood that the
 25 invention includes all possible enantiomers arising therefrom and mixtures thereof including racemates.

The term alkyl as a group or part of a group e.g. alkoxy, alkylthio, alkylamino, dialkylamino, optionally substituted alkyl e.g. aminoalkyl, cycloalkylalkyl, aralkyl, heteroarylalkyl or heterocyclalkyl refers to a C₁₋₆ straight or branched chain alkyl group.

The term halogen includes fluorine, chlorine, bromine or iodine.

The term aryl as a group or part of a group e.g. aryloxy, aralkyl or arylamino refers to an optionally substituted phenyl or fused bicyclic aryl group e.g. naphthyl. The terms aryl, optionally substituted phenyl, heteroaryl, C₃₋₇ cycloalkyl as a group or part of a group and 4-7 membered heterocycl as a group or part of a group includes such groups which are optionally substituted with 1 to 3 substituents which may be the same or different and selected from halogen, aryl, heteroaryl, heterocyclalkyl, hydroxy, alkyl, alkoxy, trifluoroalkyl, amino, alkylamino, dialkylamino, arylamino, heteroarylamino, heterocyclamino, acylamino, aminoalkyl, alkylaminoalkyl, dialkylaminoalkyl, acylaminoalkyl, arylaminoalkyl, heteroarylaminoalkyl, cycloalkylaminoalkyl, heterocyclaminoalkyl, hydroxyalkyl, CONR⁴R⁵, CSNR⁴R⁵, CH₂CONR⁴R⁵, carboxy, carboxamido, alkoxycarbonyl, aminoalkoxy, dialkylaminoalkoxy, acylaminoalkoxy, sulphonamido, aminosulphonyl, cyano, formyl, nitro, R⁶O or R⁶S(O)_n wherein R⁶ is a group selected from alkyl, aryl, heteroaryl or heterocyclalkoxy and n is zero, one or two, or each of the said groups can form part of a fused bicyclic ring system containing up to 10 ring members and which can be at least partially saturated.

The term heteroaryl as a group or part of a group e.g. heteroaryloxy refers to a 5, or 6 membered ring or a fused 5,6 or 6,6 bicyclic ring system. When heteroaryl represents a 5 membered group it contains a heteroatom selected from O, N or S and may optionally contain a further 1 to 3 nitrogen atoms. Examples of such groups include furanyl, thienyl, isoxazolyl, oxazolyl or imidazolyl.

When heteroaryl represents a 6-membered group it contains from 1 to 3 nitrogen atoms. Examples of such groups include pyridyl, pyrimidinyl, or triazinyl. The term 5,6 fused bicyclic heteroaryl group refers to a group in which the 5-membered ring contains an oxygen, sulphur or NH group and may optionally contain a further 1 to 2 nitrogen atoms, and the 6 membered ring optionally contains from 1

to 3 nitrogen atoms. Examples of such groups include benzofuranyl, benzothienyl, benzimidazole, benzotriazole or indolyl.

The term 6,6-fused bicyclic heteroaryl group refers to a bicyclic heteroaryl group which contains at least one nitrogen atom in one of the rings and may contain up to 3 nitrogen atoms in each ring. Examples of such groups include quinolinyl, isoquinolinyl or naphthyridinyl also the term 6,6 fused bicyclic heteroaryl group refers to a 6-membered heteroaryl group which is fused to a partially saturated carbocyclic group. Examples of such a group includes tetrahydroquinolinyl or tetrahydroisoquinolinyl.

The term heterocyclyl as a group or part of a group e.g. heterocyclylalkyl or heterocyclylalkylidene refers to a bridged heterocyclic group or a 4-7 membered heterocyclyl group which is linked to the rest of the compound of formula (1) via a carbon or nitrogen atom in that group and which contains one or two hetero atoms selected from N, O or S(O)_n, and when the heterocyclyl group contains a ring member NH or the heterocyclyl group is substituted by a primary or secondary amino group then the term also includes N-alkyl, N-optionally substituted phenyl, N-araalkyl, N-sulfonyl, or, N-acyl derivatives thereof. The term heterocyclic also includes bridged heterocyclic. Examples of such heterocyclic groups include optionally substituted pyrrolidine, piperidine, piperazine, homopiperazine, morpholine, thiomorpholine and (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amine.

The term cycloalkyl as a group or part of a group e.g. cycloalkylalkyl or cycloalkylidene refers to a 3-7 membered carbocyclic group.

The term fused bicyclic ring system containing up to 11 ring members and which is at least partially saturated includes carbocyclic and heterocyclic 6,5, 6,6 and 6,7 bicyclic ring systems. Examples of such 6,5 and 6,6 carbocyclic ring systems include those wherein the bicyclic ring comprises a benzene ring fused to a 5-, 6- or -membered carbocyclic ring which is at least partially saturated e.g. tetrahydronaphthyl, indanyl or indenyl. Examples of such 6,5, 6,6 or 6,7 heterocyclic rings include those wherein one ring is benzene which is fused to a 5, 6 or 7 membered ring containing one or two hetero atoms selected from O, S or N e.g. indolinyl, isoindolinyl, 2,3-dihydro-1H-isoindol-5-yl, dihydrobenzofuranyl,

dihydrobenzothienyl, 1,3-benzodioxolyl, benzopyrrolyl, 1,3-benzodithiolyl, 1,4-benzodioxanyl, chromanyl, chromenyl or 2,3,4,5-tetrahydro-1H-benzo[c]azepin-8-yl. The term acyl as a group or part of the acylamino group refers to an alkanoyl, aroyl, aralkanoyl, alkoxycarbonyl, aryloxycarbonyl or aralkoxycarbonyl group.

- 5 The compounds of formula (I) form salts with inorganic and organic acids and the invention includes such salts formed with physiologically acceptable inorganic and organic acids.

- The group R^1 is preferably a group such as, but not limited to, C_{1-6} alkyl such as ethyl, C_{3-7} cycloalkylalkyl e.g. C_{3-7} cycloalkylmethyl such as cyclopropylmethyl, 10 optionally substituted phenyl such as phenyl or phenyl substituted by hydroxy, amino eg methansulfonylamino, alkoxy, e.g. 2-dimethylaminoethoxy, 2-methylaminoethoxy, aminoethoxy, heterocyclalkoxy e.g. N-methyl-pyrrolidino-2-ylmethoxy, 6,6 fused bicyclic heterocyclic e.g. 2-methyl tetrahydroisoquinolin-7-yl, 2-(aminoacetyl)-tetrahydroisoquinolin-7-yl, 2-(aminocarbonylmethyl)- 15 tetrahydroisoquinolin-7-yl or tetrahydroisoquinolin-7-yl.

 The group X is preferably, but not limited to, O or S.

- Preferred examples of R^2 include, but are not limited to, alkyl, e.g. methyl, acetylaminomethyl, [1-(2-methylpropanoyl)proline]-3-yl, aralkyl, e.g. benzyl, cycloalkyl, e.g. cyclopentyl, alkenyl, e.g. 2-methoxycarbonyl ethenyl, 20 optionally substituted phenyl (e.g. phenyl or phenyl substituted by one or two groups selected from alkyl, e.g. methyl, isopropyl, 1-hydroxyethyl, 1-hydroxy-1-methylpropyl, alkylthioether, e.g. methylthio, alkylsulfinyl, e.g. methylsulfinyl, alkylsulfonyl, e.g. methylsulfonyl, alkoxy e.g. methoxy or ethoxy, hydroxy, hydroxymethyl, methoxycarbonylmethyl, carboxymethyl, trifluoromethyl, amino, 25 alkylamino, e.g. dimethylamino, alkylthionoamido, e.g. thionoacetamido, alkylamido e.g., acetamido, propanamido, methoxyacetamido, butanamido, 2-methylpropanamido, 2-methoxypropanamido, N-methyl-acetamido, cyclopropylacetamido, heteroaraalkylamido, e.g., 5-methyl-thioazol-2-ylacetamido, 1,5-dimethylpyrazol-4-ylacetamide, arylamido, e.g. 4-ethoxybenzimidazole, 4-methoxybenzamido, 3-methoxybenzamido, 4-cyanobenzamido, heteroaryl amido, e.g. 3-pyridylamido, 2-furanyl amido, benzamido, 4-fluorobenzamido, carboxyl, 30 methoxycarbonyl, carboxamido, e.g. carboxamido, N,N-dimethylcarboxamide, N-

methylcarboxamide, N-(2-methoxyethyl)carboxamido, N-(3-ethoxypropyl)carboxamido, N-ethylcarboxamido, piperidincarbonyl, aminoalkylcarboxamido, e.g. 2-morpholinoethylcarboxamido, 3-morpholinopropylcarboxamido, ureido, e.g. ureido, N'-methylureido, N'-benzylureido, N',N'-morpholinureido, N'-phenylureido, alkylsulfonamido, e.g. methansulfonamido, butansulfonamido, arylsulfonamido, e.g. 4-fluorobenzenesulfonamido, 4-methylbenzenesulfonamido, 4-methoxybenzenesulfonamido, sulfonyl urea, e.g. dimethylaminosulfonamide, halogen, e.g. fluoro, chloro, acyl, e.g. acetyl, propanoyl, cyano, nitro, or heterocyclyl e.g. morpholino), heteroaryl, e.g. 2-imidazolyl, 2-thioazolyl, 2,5-dimethylfuran-3-yl, 2-pyridyl, chromenyl, 7-methoxy-benzothiazol-2-yl, 7-aza-benzothiazol-2-yl,

Examples of suitable compounds according to the invention include those listed below and found in Examples 1-24.

3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}phenol,
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}phenyl)acetamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}phenyl)ethanethioamide;
 4-(6-{[3,4-Bis(methyloxy)phenyl]thio}-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine;
 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}benzoate;
 4-(1-Ethyl-6-{[3-(methyloxy)phenyl]thio}-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine;
 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}benzoic acid;
 4-(1-Ethyl-6-{[2-(methyloxy)phenyl]thio}-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine;
 4-[1-Ethyl-6-(1*H*-imidazol-2-ylthio)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furazan-3-amine;
 4-[6-(Cyclopentylthio)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furazan-3-amine;
 4-[1-Ethyl-6-(1,3-thiazol-2-ylthio)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furazan-3-amine;

- 4-{1-Ethyl-6-[(phenylmethyl)thio]-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-furan-3-amine;
4-[1-Ethyl-6-(phenylthio)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furan-3-amine;
methyl 2-{[2-(4-amino-furan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}benzoate;
- 5 *N*-(4-{[2-(4-Amino-furan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}phenyl)acetamide;
4-{6-[(3-Chloro-4-fluorophenyl)thio]-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-furan-3-amine;
4-{[2-(4-Amino-furan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}benzoic
10 acid;
N-(2-{[2-(4-Amino-furan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}ethyl)acetamide;
4-{6-[(2,5-dimethyl-3-furanyl)thio]-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-furan-3-amine;
- 15 4-[1-Ethyl-6-(phenylsulfinyl)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furan-3-amine;
4-{6-[(3,4-Dichlorophenyl)thio]-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-furan-3-amine;
4-[1-Ethyl-6-(2-pyridinylthio)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furan-3-amine;
4-{1-Ethyl-6-[(4-fluorophenyl)thio]-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-furan-3-
20 amine;
7-{[2-(4-Amino-furan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}-3-methyl-2*H*-chromen-2-one;
4-(1-Ethyl-6-{[4-(trifluoromethyl)phenyl]thio}-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furan-3-amine;
- 25 1-((2*S*)-3-{[2-(4-Amino-furan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}-2-methylpropanoyl)-L-proline;
4-(1-Ethyl-6-{[4-(methylthio)phenyl]thio}-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furan-3-amine;
4-[1-Ethyl-6-(4-pyridinylthio)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furan-3-amine;
- 30 4-[1-Ethyl-6-([1,3]thiazolo[4,5-*b*]pyridin-2-ylthio)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furan-3-amine;

- 4-(1-Ethyl-6-{[5-(methyloxy)-1,3-benzothiazol-2-yl]thio}-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine;
Methyl (2*E*)-3-(4-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}phenyl)-2-propenoate;
- 5 4-(1-Ethyl-6-{[4-(methylsulfonyl)phenyl]sulfinyl}-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine;
4-(1-Ethyl-6-{[4-(methylsulfinyl)phenyl]sulfinyl}-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine;
4-{6-[(4-Fluorophenyl)oxy]-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-furazan-3-
- 10 amine;
4-(1-Ethyl-6-{[3-(methyloxy)phenyl]oxy}-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine;
4-{6-[(3,4-Dimethylphenyl)oxy]-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-furazan-3-amine;
- 15 *N*-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetamide;
4-{6-[(3-Aminophenyl)oxy]-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-furazan-3-amine;
4-{6-[(4-Aminophenyl)oxy]-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-furazan-3-
- 20 amine;
3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}benzonitrile;
1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)ethanone;
- 25 *N*-(4-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetamid;
4-(1-Ethyl-6-{[3-(1-methylethyl)phenyl]oxy}-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine;
4-(6-{[3-(Dimethylamino)phenyl]oxy}-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-
- 30 furazan-3-amine;
4-(1-Ethyl-6-{[3-(4-morpholinyl)phenyl]oxy}-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine;

- N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-4-methylbenzenesulfonamide;
 4-(1-Ethyl-7-{[3-(methyloxy)phenyl]oxy}-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine;
- 5 1,1-Dimethylethyl (3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)carbamate;
 4-{2-(4-Amino-furazan-3-yl)-6-[(4-fluorophenyl)oxy]-1*H*-imidazo[4,5-*c*]pyridin-1-yl}phenol;
 4-{6-[(3-Aminophenyl)oxy]-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-furazan-3-
- 10 amine;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)methanesulfonamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetamide;
- 15 *N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-*N'*-methylurea;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetamide;
N-(4-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetamide;
- 20 Methyl 4-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}benzoate;
 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}benzoate;
- 25 4-[6-[(4-Fluorophenyl)oxy]-1-(2-methyl-1,2,3,4-tetrahydro-7-isoquinoliny)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furazan-3-amine;
 1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)ethanol;
 2-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-2-butanol;
- 30 6-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}-3,4-dihydro-1(2*H*)-naphthalenone;

- N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-*N'*-(phenylmethyl)urea;
Methyl (3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetate;
- 5 (3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetic acid;
4-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}benzonitrile;
3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}benzoic
10 acid;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(methylamino)ethyl]oxy}phenyl)-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetamide;
N-(3-{[1-{4-[(2-Aminoethyl)oxy]phenyl}-2-(4-amino-furazan-3-yl)-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetamide;
- 15 *N*-[3-({2-(4-Amino-furazan-3-yl)-1-[4-({[(2*S*)-1-methyl-2-pyrrolidinyl]methyl}oxy)phenyl]-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy)phenyl]acetamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)benzamide;
- 20 *N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-4-fluorobenzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-2-furancarboxamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-2-methylpropanamide;
- 25 *N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)butanamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-2-(methyloxy)acetamide;
- 30 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenol;
Methyl 3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}benzoate;

- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}benzoic acid;
- N*-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}phenyl)-4-morpholinecarboxamide;
- 5 *N*-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}phenyl)benzamide;
- N*-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}phenyl)-4-fluorobenzenesulfonamide;
- N*-(4-{{2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}phenyl)acetamide;
- 10 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}-*N,N*-dimethylbenzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}-*N*-methylbenzamide;
- 15 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}benzamide;
- 4-(1-Phenyl-6-{{3-(1-piperidinylcarbonyl)phenyl}oxy}-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}-*N*-ethylbenzamide;
- 20 *N*-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}phenyl)-*N*-methylacetamide;
- N*-(3-{{2-(4-Amino-furazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinoliny)-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}phenyl)acetamide;
- 25 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}-*N*-[2-(methyloxy)ethyl]benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}-*N*-[2-(4-morpholinyl)ethyl]benzamide;
- 1-(3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}phenyl)ethanone;
- 30 *N*-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}phenyl)-*N*'-phenylurea;

- N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)benzenesulfonamide;
- N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-*N,N*-dimethylsulfamide;
- 5 *N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-1-butanesulfonamide;
- N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-3-pyridinecarboxamide;
- 4-{1-Athyl-6-[(phenylmethyl)oxy]-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-furazan-3-amine;
- 10 *N*-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)methanesulfonamide;
- 4-{6-[(3-Nitrophenyl)oxy]-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-furazan-3-amine;
- N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-4-cyanobenzamide;
- 15 *N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)cyclohexanecarboxamide;
- N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-3-(methyloxy)benzamide;
- 20 *N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-4-(dimethylamino)benzamide;
- N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)benzamide;
- N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)urea;
- 25 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}-*N*-(cyclopropylmethyl)benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}-*N*-[(4-methyl-1,3-thiazol-2-yl)methyl]benzamide;
- 30 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}-*N*-[(1,5-dimethyl-1*H*-pyrazol-4-yl)methyl]benzamide;

- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}-*N*-[3-(4-morpholinyl)propyl]benzamide;
- 4-[6-[(4-Fluorophenyl)oxy]-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furazan-3-amine;
- 5 4-[2-(4-Amino-furazan-3-yl)-6-bromo-1*H*-imidazo[4,5-*c*]pyridin-1-yl]phenol;
N-[5-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}thio}-2-(methyloxy)phenyl]acetamide;
- 1-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}phenyl)-1-propanone;
- 10 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}-*N*-[3-(ethyloxy)propyl]benzamide;
- N*-(4-{2-(4-Amino-furazan-3-yl)-6-[(4-fluorophenyl)oxy]-1*H*-imidazo[4,5-*c*]pyridin-1-yl}phenyl)methanesulfonamide;
- 4-{1-[2-(Aminoacetyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]-6-[(4-fluorophenyl)oxy]-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-furazan-3-amine;
- 15 *N*-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}phenyl)-4-(ethyloxy)benzamide;
- N*-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}phenyl)-3-methylbutanamide;
- 20 4-({[(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}phenyl)amino]carbonyl}amino)benzoic acid;
- 4-[6-Bromo-1-(4-{{2-(dimethylamino)ethyl}oxy}phenyl)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furazan-3-amine;
- 2-[7-{2-(4-Amino-furazan-3-yl)-6-[(4-fluorophenyl)oxy]-1*H*-imidazo[4,5-*c*]pyridin-1-yl}-3,4-dihydro-2(1*H*)-isoquinolinyl]acetamide;
- 25 3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}amino}benzenethiol;
- 2-(4-Amino-furazan-3-yl)-1-ethyl-*N*-(phenylmethyl)-1*H*-imidazo[4,5-*c*]pyridin-6-amine;
- 30 4-[6-[(4-Fluorophenyl)oxy]-1-(4-{{2-(methylamino)ethyl}oxy}phenyl)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furazan-3-amine;

- 4-{2-(4-Amino-furazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl}-2-chlorophenol;
- 4-{1-(3-Chloro-4-{[2-(dimethylamino)ethyl]oxy}phenyl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 5 3-{[2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
- N-[2-(Acetylamino)ethyl]-3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-
- 10 (tetrahydro-2-furanylmethyl)benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(dimethylamino)ethyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]benzamide;
- 15 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(2-pyridinyl)ethyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(dimethylamino)propyl]benzamide;
- 4-[6-(1H-Benzimidazol-4-yloxy)-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-
- 20 3-amine;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-6-methyl-3-pyridinecarboxamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-methyl-3-pyridinecarboxamide;
- 25 4-{1-[4-(Aminomethyl)phenyl]-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(1H-imidazol-1-yl)propyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-
- 30 (1-pyrrolidinyl)ethyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-hydroxyphenyl)ethyl]benzamide;

- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(3-pyridinyl)ethyl]benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(phenyloxy)ethyl]benzamide;
- 5 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-{2-[3,5-bis(methyloxy)phenyl]ethyl}benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-(1,3-benzodioxol-5-ylmethyl)benzamide;
- 10 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-(1,4-dioxan-2-ylmethyl)benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-(4-pyridinylmethyl)benzamide;
- 15 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(1-pyrrolidinyl)propyl]benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(4-pyridinyl)ethyl]benzamide;
- 20 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-(2-cyanoethyl)benzamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy})-2-methylphenyl)acetamide;
- 25 7-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-4-methyl-2(1H)-quinolinone;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-2-(dimethylamino)-5-pyrimidinecarboxamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-2-(methyloxy)-3-pyridinecarboxamide;
- 30 N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-(1-piperidinyl)benzamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)-3-(trifluoromethyl)benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-fluoro-4-(methyloxy)benzamide;
5 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-chloro-4-(methyloxy)benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(4-morpholinyl)benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-methyl-1,3-thiazole-5-carboxamide;
10 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-1-methyl-1H-1,2,3-benzotriazole-5-carboxamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-carboxamide;
15 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)benzamide;
N-[(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)carbonyl]-beta-alanine;
3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(3-
20 amino-3-oxopropyl)benzamide;
N-[4-(Aminomethyl)phenyl]-3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
4-[6-(1H-Benzimidazol-5-yloxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-
amine;
25 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]oxy}benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)pyrazolo[1,5-a]pyridine-3-carboxamide;
30 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-1-methyl-1H-imidazole-2-carboxamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-6-[(2,2,2-trifluoroethyl)oxy]-3-pyridinecarboxamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(3,5-dimethyl-1H-pyrazol-1-yl)benzamide;
 5 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(trifluoromethyl)-3-pyridinecarboxamide;
 4-[2-(4-Amino-furazan-3-yl)-6-(methyloxy)-1H-imidazo[4,5-c]pyridin-1-yl]phenol;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(1H-imidazol-1-yl)benzamide;
 10 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-6-(1H-pyrazol-1-yl)-3-pyridinecarboxamide;
 4-[1-(4-{[2-(Dimethylamino)ethyl]oxy}phenyl)-6-(methyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(dimethylamino)ethyl]oxy}benzamide;
 15 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-1-methyl-4-piperidinecarboxamide;
 4-{2-(4-Amino-furazan-3-yl)-6-[(3-aminophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl}phenyl 4-(methyloxy)benzoate;
 20 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(dimethylamino)butanamide;
 4-{2-(4-Amino-furazan-3-yl)-6-[(3-aminophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl}phenyl 2-methylpropanoate;
 N'-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N,N-dimethylsulfamide;
 25 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)methanesulfonamide;
 30 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3,4-bis(methyloxy)benzamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2,3-dihydro-1-benzofuran-5-carboxamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-chloro-2-pyridinecarboxamide;
5 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-6-methyl-3-pyridinecarboxamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(dimethylamino)butanamide;
5-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-1,3-
10 dimethyl-1,3-dihydro-2H-benzimidazol-2-one;
3-{[2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
15 3-({2-(4-Amino-furazan-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[2-(4-morpholinyl)ethyl]benzamide;
3-({2-(4-Amino-furazan-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
N'-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N,N-dimethylsulfamide;
20 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-methylpropanamide;
Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
25 3-{[2-(4-Amino-furazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoic acid;
3-{[2-(4-Amino-furazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N'-methylurea;
30 3-{[2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;

- 3-({2-(4-Amino-furazan-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-{{4-(methyloxy)phenyl}methyl}benzamide;
- 5 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[4-(methyloxy)phenyl]benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[4-(dimethylamino)phenyl]benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-
- 10 (dimethylamino)phenyl]benzamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-(dimethylamino)benzamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-(methyloxy)benzamide;
- 15 3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(4-
- 20 methyl-1-piperazinyl)propyl]benzamide;
- 4-(Aminomethyl)-N-(3-{{2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)benzamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-3-(3-pyridinyl)propanamide;
- 25 4-(Aminomethyl)-N-(3-{{2-(4-amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)benzamide;
- Methyl 3-{{2-(4-amino-furazan-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}benzoate;
- 3-{{2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[4-(dimethylamino)phenyl]benzamide;
- 30 3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[4-(4-morpholinyl)phenyl]benzamide;

- 3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[4-(methyloxy)phenyl]benzamide;
N-(3-([2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)phenyl)-3-(4-morpholinyl)propanamide;
- 5 3-([2-(4-Amino-furazan-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy)benzoic acid;
3-([2-(4-Amino-furazan-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
3-([2-(4-Amino-furazan-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-
- 10 6-yl]oxy)-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
4-{1-Ethyl-6-([3-([3-(4-morpholinyl)propyl]oxy)phenyl]oxy)-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
1-{3-([3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)phenyl]oxy)propyl}-2-pyrrolidinone;
- 15 4-{6-([3-([3-(4-Acetyl-1-piperazinyl)propyl]oxy)phenyl]oxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
1-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)phenyl)-4-(4-morpholinyl)-1-butanone;
3-([2-(4-Amino-furazan-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[2-(4-
- 20 morpholinyl)ethyl]benzamide;
3-([2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
3-([2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
- 25 3-([2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[2-(4-morpholinyl)ethyl]benzamide;
3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-(4-([2-(4-morpholinyl)ethyl]oxy)phenyl)benzamide;
3-([2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[2-
- 30 (4-morpholinyl)ethyl]benzenesulfonamide;
N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)phenyl)-3-(3-hydroxyphenyl)propanamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-(4-hydroxyphenyl)propanamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(2-oxo-1-pyrrolidiny)butanamide;
- 5 3-({2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(2-oxo-1-pyrrolidiny)propyl]benzamide;
- 3-({2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[2-(4-morpholiny)ethyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{2-[4-
10 hydroxy-3-(methyloxy)phenyl]ethyl}benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-(2-oxo-1-pyrrolidiny)propanamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(2-oxo-1-pyrrolidiny)butanamide;
- 15 3-{[2-(4-Amino-furazan-3-yl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholiny)ethyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(4-piperidinylmethyl)benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-
20 piperidinyl)ethyl]benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholiny)ethyl]oxy}benzamide;
- N-[2-(4-Acetyl-1-piperazinyl)ethyl]-3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
- 25 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)benzamide; and
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-
30 6-yl]oxy}phenyl)-4-{[2-(4-morpholiny)ethyl]oxy}benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(4-{[3-(dimethylamino)propyl]oxy}phenyl)benzamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[3-(1-piperidiny)propyl]oxy}benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(diethylamino)ethyl]oxy}benzamide;
 5 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(1-pyrrolidiny)ethyl]oxy}benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-({2-[bis(1-methylethyl)amino]ethyl}oxy)benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(1-piperidiny)ethyl]oxy}benzamide;
 10 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-hydroxybenzamide;
 N-[4-(Acetylamino)phenyl]-3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
 15 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(2-oxo-2-phenylethyl)benzamide;
 N-[4-(Aminocarbonyl)phenyl]-3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-
 20 hydroxy-2-(4-hydroxyphenyl)ethyl]benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-(6-methyl-2-pyridiny)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidiny)propyl]benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-(6-methyl-2-pyridiny)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholiny)ethyl]benzamide;
 25 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-6-{[2-(4-morpholiny)ethyl]oxy}-3-pyridinecarboxamide;
 4-{1-Ethyl-6-[(3-{[2-(4-morpholiny)ethyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-
 30 thiomorpholiny)ethyl]benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]benzamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[3-(1-piperazinyl)propyl]oxy}benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]benzamide;
 5 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(1-oxido-4-thiomorpholinyl)ethyl]benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(1-piperidiny)propyl]benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-[(1-methyl-4-piperidiny)oxy]benzamide;
 10 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-(4-piperidiny)propanamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(1-piperazinyl)ethyl]oxy}benzamide;
 15 1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(4-morpholinyl)-1-butanol;
 4-[1-Ethyl-6-({3-[(1E)-3-(4-methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]phenyl}oxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
 4-[1-Ethyl-6-({3-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]phenyl}oxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
 20 3-({2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide;
 25 1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-methyl-4-(4-morpholinyl)-1-butanone;
 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl}benzamide;
 1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(4-methyl-1-piperazinyl)-4-oxo-1-butanone;
 30 4-(1-(1,2,3,4-Tetrahydro-7-isoquinolinyl)-6-{[4-(trifluoromethyl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(4-morpholinyl)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(4-morpholinyl)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- 5 3-({2-(4-Amino-furazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 3-({2-(4-Amino-furazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[2-(4-morpholinyl)ethyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-(2-methyl-4-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
- 10 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(1,3-benzodioxol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
- 3-{[2-(4-Amino-furazan-3-yl)-1-(1,3-benzodioxol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 15 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(1H-indazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
- 3-{[2-(4-Amino-furazan-3-yl)-1-(1H-indazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(1-pyrrolidinyl)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- 20 3-({2-(4-Amino-furazan-3-yl)-1-[2-(dimethylamino)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
- 25 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
- Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(1H-benzimidazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-(4-morpholinylmethyl)benzamide;
- 30 N-[3-{[2-(4-Amino-furazan-3-yl)-1-ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy]-5-(trifluoromethyl)phenyl]acetamide;

- 4-(6-{[3-Amino-5-(trifluoromethyl)phenyl]oxy}-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(dimethylamino)propyl]-N-methylbenzamide;
- 5 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(diethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{4-[(dimethylamino)methyl]phenyl}benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{4-[2-(dimethylamino)ethyl]phenyl}benzamide;
- 10 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{4-[2-(1-pyrrolidinyl)ethyl]phenyl}benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(1-methyl-4-piperidiny)propyl]benzamide;
- 15 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-methyl-N-[3-(1-methyl-4-piperidiny)propyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-(4-piperidiny)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 20 3-{[2-(4-Amino-furazan-3-yl)-1-(1H-benzimidazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperaziny)-3-oxopropyl]benzamide;
- 25 3-{[2-(4-Amino-furazan-3-yl)-1-(4-piperidiny)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperaziny)-3-oxopropyl]benzamide;
- 4-(1-(4-{[2-(Dimethylamino)ethyl]oxy}phenyl)-6-{[3-(methylsulfonyl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
- 3-{[2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(1-methyl-4-piperidiny)propyl]benzamide;
- 30 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-[(dimethylamino)methyl]benzamide;

- N-[3-({2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)phenyl]acetamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-methyl-1-piperazinyl)ethyl]benzamide;
- 5 N-[3-({2-(4-Amino-furazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)phenyl]acetamide;
- 4-{1-Ethyl-6-[(3-{[3-(1-methyl-4-piperidiny)propyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 3-{[2-(4-Amino-furazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinoliny)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidiny)propyl]benzamide;
- 10 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(1-piperidiny)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- N-{3-[(2-(4-Amino-furazan-3-yl)-1-{4-[(cyanomethyl)oxy]phenyl})-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl]acetamide;
- 15 4-(1-Ethyl-6-{[3-(1H-imidazol-1-yl)phenyl]oxy})-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
- 4-(1-Ethyl-6-{[3-(1,3-thiazol-5-yl)phenyl]oxy})-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
- 4-(1-Ethyl-6-{[3-(1,3-oxazol-5-yl)phenyl]oxy})-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
- 20 4-(1-Ethyl-6-{[3-(methylsulfonyl)phenyl]oxy})-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
- N~1~(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N~3~,N~3~-dimethyl-beta-alaninamide;
- 25 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(4-morpholiny)butanamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(diethylamino)butanamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methylamino)butanamide;
- 30 N-(5-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-2-methylphenyl)acetamide;

- N-(5-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-2-chlorophenyl)acetamide;
- 4-{1-Ethyl-6-[(3-{[2-(1-methyl-4-piperidinyl)ethyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 5 4-{1-Ethyl-6-[(3-{[4-(1-methyl-4-piperidinyl)butyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 4-{1-(2,3-Dihydro-1H-isoindol-5-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 4-{1-Ethyl-6-[(3-{[(1-methyl-4-piperidinyl)methyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 10 4-{1-Ethyl-6-[(3-{[(1-methyl-3-piperidinyl)methyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 4-{1-Ethyl-6-[(3-{[2-(1-methyl-3-piperidinyl)ethyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 15 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(2-methyl-1,3-benzoxazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
- 4-[1-Ethyl-6-({3-[4-(1-methyl-4-piperidinyl)butyl]phenyl}oxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
- Methyl 3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
- 20 yl]methyl}benzoate
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]methyl}-N-[2-(4-morpholinyl)ethyl]benzamide;
- 1-(3-{[2-(4-Amino-furazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinoliny)]-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)ethanone.

25

Preferred Compound:

- 4-[1-Ethyl-6-(phenylthio)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
- 4-{1-Ethyl-6-[(4-fluorophenyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 30 4-[1-Ethyl-6-(2-pyridinylthio)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
- 4-(1-Ethyl-6-{[3-(methyloxy)phenyl]thio}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;

- 4-[1-Ethyl-6-(phenylsulfinyl)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
 4-{1-Ethyl-6-[(phenylmethyl)thio]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
 4-(6-{[3,4-Bis(methyloxy)phenyl]thio}-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-
 furazan-3-amine;
- 5 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio}phenol;
 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
 yl]thio}benzoate;
- 4-[1-Ethyl-6-(1,3-thiazol-2-ylthio)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
 10 yl]thio}phenyl)acetamide;
- 4-[1-Ethyl-6-([1,3]thiazolo[4,5-b]pyridin-2-ylthio)-1H-imidazo[4,5-c]pyridin-2-yl]-
 furazan-3-amine;
- 4-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio}benzoic
 acid;
- 15 N-(2-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
 yl]thio}ethyl)acetamide;
- 4-[1-Ethyl-6-(1H-imidazol-2-ylthio)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-
 amine;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio}benzoic
 20 acid;
- 4-(1-Ethyl-6-{[4-(trifluoromethyl)phenyl]thio}-1H-imidazo[4,5-c]pyridin-2-yl)-
 furazan-3-amine;
- 4-{6-[(3,4-Dichlorophenyl)thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-
 amine;
- 25 4-{6-[(3-Chloro-4-fluorophenyl)thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl}-
 furazan-3-amine;
- Methyl 2-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
 yl]thio}benzoate;
- 4-(1-Ethyl-6-{[2-(methyloxy)phenyl]thio}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-
 30 3-amine;
- 4-(1-Ethyl-6-{[4-(methylthio)phenyl]thio}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-
 3-amine;

- 4-(1-Ethyl-6-{[4-(methylsulfinyl)phenyl]sulfinyl}-1H-imidazo[4,5-c]pyridin-2-yl)-
furazan-3-amine;
- 4-(1-Ethyl-6-{[4-(methylsulfonyl)phenyl]sulfinyl}-1H-imidazo[4,5-c]pyridin-2-yl)-
furazan-3-amine;
- 5 4-(1-Ethyl-6-{[5-(methyloxy)-1,3-benzothiazol-2-yl]thio}-1H-imidazo[4,5-c]pyridin-
2-yl)-furazan-3-amine;
- 4-[6-(Cyclopentylthio)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
- 1-((2S)-3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio}-
2-methylpropanoyl)-L-proline;
- 10 4-{6-[(2,5-Dimethyl-3-furanyl)thio]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl}-
furazan-3-amine;
- 4-[1-Ethyl-6-(4-pyridinylthio)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
yl]thio}phenyl)ethanethioamide;
- 15 7-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio}-3-
methyl-2H-chromen-2-one;
- N-[5-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio}-2-
(methyloxy)phenyl]acetamide;
- Methyl (2E)-3-(4-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
yl]thio}phenyl)-2-propenoate;
- 20 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(4-
{[3-(dimethylamino)propyl]oxy}phenyl)benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{4-[2-
(1-pyrrolidinyl)ethyl]phenyl}benzamide;
- 25 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{4-
[(dimethylamino)methyl]phenyl}benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{4-[2-
(dimethylamino)ethyl]phenyl}benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
yl]oxy}phenyl)-4-{[2-(dimethylamino)ethyl]oxy}benzamide;
- 30 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(1-
methyl-4-piperidinyl)propyl]benzamide;

- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-[(dimethylamino)methyl]benzamide;
5 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(diethylamino)ethyl]oxy}benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-({[2-[bis(1-methylethyl)amino]ethyl]oxy}benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(1-piperidinyl)ethyl]oxy}benzamide;
10 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-methyl-1-piperazinyl)ethyl]benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
15 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(4-{[2-(4-morpholinyl)ethyl]oxy}phenyl)benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(1-pyrrolidinyl)ethyl]oxy}benzamide;
4-(Aminomethyl)-N-(3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)benzamide;
20 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-(3-pyridinyl)propanamide;
3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-piperidinyl)ethyl]benzamide;
25 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{2-[4-hydroxy-3-(methyloxy)phenyl]ethyl}benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[4-(4-morpholinyl)phenyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-(4-piperidinyl)propanamide;
30 3-{[2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(1-methyl-4-piperidinyl)propyl]benzamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-1-methyl-1H-1,2,3-benzotriazole-5-carboxamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-(4-hydroxyphenyl)propanamide;
- 5 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(2-oxo-2-phenylethyl)benzamide;
1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(4-methyl-1-piperazinyl)-4-oxo-1-butanone;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(4-morpholinylmethyl)benzamide;
- 10 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]oxy}benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide;
- 15 N-[4-(Acetyl amino)phenyl]-3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[4-(dimethylamino)phenyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-pyridinecarboxamide;
- 20 4-[2-(4-Amino-furazan-3-yl)-6-(methyloxy)-1H-imidazo[4,5-c]pyridin-1-yl]phenol;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(dimethylamino)butanamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(diethylamino)butanamide;
- 25 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]benzamide;
- 30 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]benzamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[3-(1-piperidinyl)propyl]oxy}benzamide;
N-[4-(Aminocarbonyl)phenyl]-3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
- 5 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]oxy}benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(4-piperidinylmethyl)benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methylamino)butanamide;
- 10 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-hydroxyphenyl)ethyl]benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl}benzamide;
- 15 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(1-piperidinyl)propyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
4-{1-Ethyl-6-[(3-{[4-(1-methyl-4-piperidinyl)butyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 20 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(1H-imidazol-1-yl)benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(4-morpholinyl)butanamide;
- 25 3-{[2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[4-(methyloxy)phenyl]benzamide;
1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(4-morpholinyl)-1-butanone;
- 30 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3,4-bis(methyloxy)benzamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-6-methyl-3-pyridinecarboxamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-thiomorpholinyl)ethyl]benzamide;
- 5 N-[4-(Aminomethyl)phenyl]-3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2,3-dihydro-1-benzofuran-5-carboxamide;
 N-[2-(4-Acetyl-1-piperazinyl)ethyl]-3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
- 10 3-{[2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
 N-[3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-5-(trifluoromethyl)phenyl]acetamide;
- 15 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)urea;
 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-hydroxybenzamide;
- 20 3-{[2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(4-morpholinyl)benzamide;
- 25 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)benzamide;
 N-(3-{[1-{4-[(2-Aminoethyl)oxy]phenyl}-2-(4-amino-furazan-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-6-methyl-3-pyridinecarboxamide;
- 30 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-methyl-1,3-thiazole-5-carboxamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(dimethylamino)butanamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[3-(1-piperazinyl)propyl]oxy}benzamide;
- 5 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-(dimethylamino)-5-pyrimidinecarboxamide;
- 3-({2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
- 4-{1-Ethyl-6-[(3-{[2-(1-methyl-4-piperidinyl)ethyl]oxy}phenyl)oxy]-1H-
- 10 imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-furancarboxamide;
- 15 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(3-pyridinyl)ethyl]benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-[(1-methyl-4-piperidinyl)oxy]benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(methylamino)ethyl]oxy}phenyl)-1H-
- 20 imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- N-[3-({2-(4-Amino-furazan-3-yl)-1-[4-({[(2S)-1-methyl-2-pyrrolidinyl]methyl}oxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)phenyl]acetamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
- 25 yl]oxy}phenyl)-4-(dimethylamino)benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(2-oxo-1-pyrrolidinyl)butanamide;
- N-1~(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N~3~,N~3~-dimethyl-beta-alaninamide;
- 30 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-(methyloxy)acetamide;

- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(1H-imidazol-1-yl)propyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-pyridinyl)ethyl]benzamide;
- 5 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-6-(1H-pyrazol-1-yl)-3-pyridinecarboxamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(1-pyrrolidinyl)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(1-oxido-4-thiomorpholinyl)ethyl]benzamide;
- 10 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(1-piperazinyl)ethyl]oxy}benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(1-piperidinyl)benzamide;
- 15 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(diethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- 20 4-{1-Ethyl-6-[(3-{[3-(1-methyl-4-piperidinyl)propyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenol;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(ethyloxy)benzamide;
- 25 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(1,4-dioxan-2-ylmethyl)benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-methyl-3-pyridinecarboxamide;
- 30 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)butanamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-carboxamide;
4-{2-(4-Amino-furazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl}phenol;
- 5 3-{[2-(4-Amino-furazan-3-yl)-1-(1H-benzimidazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidiny)propyl]benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(tetrahydro-2-furanylmethyl)benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-
- 10 (dimethylamino)propyl]benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(dimethylamino)butanamide;
- 15 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-fluorobenzamide;
4-(Aminomethyl)-N-(3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
- 20 yl]oxy}phenyl)-6-{[2-(4-morpholinyl)ethyl]oxy}-3-pyridinecarboxamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(1-piperidiny)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
- 25 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-chloro-4-(methyloxy)benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-(4-piperidiny)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-
- 30 (1-pyrrolidiny)propyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]oxy}benzamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-fluoro-4-(methyloxy)benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
- 5 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-(methyloxy)benzamide;
 3-({2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[2-(4-morpholinyl)ethyl]benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
- 10 yl]oxy}phenyl)-3-(3-hydroxyphenyl)propanamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
 4-[6-[(4-Fluorophenyl)oxy]-1-(1,2,3,4-tetrahydro-7-isoquinoliny)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
- 15 3-{[2-(4-Amino-furazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinoliny)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
- 20 yl]oxy}phenyl)-6-[(2,2,2-trifluoroethyl)oxy]-3-pyridinecarboxamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N'-methylurea;
 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-morpholinyl)propyl]benzamide;
- 25 N-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]oxy}benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[4-(methyloxy)phenyl]benzamide;
 4-(6-{[3-Amino-5-(trifluoromethyl)phenyl]oxy}-1-ethyl-1H-imidazo[4,5-c]pyridin-
- 30 2-yl)-furazan-3-amine;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-1-methyl-4-piperidinecarboxamide;

- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(1-pyrrolidinyl)ethyl]benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 5 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-(3-amino-3-oxopropyl)benzamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)methanesulfonamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-(4-pyridinylmethyl)benzamide;
- 10 N'-(3-{{2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-N,N-dimethylsulfamide;
- Methyl 3-{{2-(4-amino-furazan-3-yl)-1-(1H-benzimidazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}benzoate;
- 15 N-{{3-[(2-(4-Amino-furazan-3-yl)-1-{4-[(cyanomethyl)oxy]phenyl}-1H-imidazo[4,5-c]pyridin-6-yl)oxy]phenyl}acetamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(2-pyridinyl)ethyl]benzamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-N'-methylurea;
- 20 3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]benzamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)acetamide;
- 25 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 4-{1-Ethyl-6-[(3-{{[(1-methyl-4-piperidinyl)methyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)pyrazolo[1,5-a]pyridine-3-carboxamide;
- 30 N-(3-{{2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)acetamide;

- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(dimethylamino)ethyl]benzamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-(3,5-dimethyl-1H-pyrazol-1-yl)benzamide;
- 5 3-{{2-(4-Amino-furazan-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-(4-{{2-(dimethylamino)ethyl}oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)methanesulfonamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 10 4-[1-(4-{{2-(Dimethylamino)ethyl}oxy}phenyl)-6-(methyloxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-1-methyl-4-piperidinecarboxamide;
- 15 1-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)ethanone;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-cyanobenzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-(1H-indazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 20 N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-N'-(phenylmethyl)urea;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]benzamide;
- 25 N-(3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-(2-oxo-1-pyrrolidinyl)butanamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-(4-{{2-(4-morpholinyl)ethyl}oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)acetamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[4-(dimethylamino)phenyl]benzamide;
- 30 3-{{2-(4-Amino-furazan-3-yl)-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;

- 4-[6-(1H-Benzimidazol-4-yloxy)-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-furan-3-amine;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-methylpropanamide;
- 5 3-({2-(4-Amino-furazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[2-(4-morpholinyl)ethyl]benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)methanesulfonamide;
- 10 3-({2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[2-(4-morpholinyl)ethyl]benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-(methyloxy)-3-pyridinecarboxamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-morpholinecarboxamide;
- 15 N'-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N,N-dimethylsulfamide;
- N-[2-(Acetylamino)ethyl]-3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-
- 20 (methyloxy)ethyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(2-cyanoethyl)benzamide;
- 3-({2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide;
- 25 4-(1-Ethyl-6-{[3-(methylsulfonyl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furan-3-amine;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-chloro-2-pyridinecarboxamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
- 30 yl]oxy}phenyl)-4-(trifluoromethyl)-3-pyridinecarboxamide;
- N'-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N,N-dimethylsulfamide;

- 4-{6-[(3-Aminophenyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- Methyl 3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
- 5 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-methylpropanamide;
- 4-{1-Ethyl-6-[(phenylmethyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 10 N-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-(4-morpholinyl)propanamide;
- 4-[1-Ethyl-6-({3-[(1E)-3-(4-methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]phenyl}oxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N'-phenylurea;
- 15 3-{[2-(4-Amino-furazan-3-yl)-1-(1,3-benzodioxol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 4-{1-[4-(Aminomethyl)phenyl]-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 20 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoic acid;
- N-(5-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-2-chlorophenyl)acetamide;
- 4-{1-(2,3-Dihydro-1H-isoindol-5-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 25 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-methylbenzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
- 30 3-{[2-(4-Amino-furazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;

- 4-{6-[(3-{[3-(4-Acetyl-1-piperazinyl)propyl]oxy}phenyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl}-furan-3-amine;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-1-methyl-1H-imidazole-2-carboxamide;
- 5 3-({2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide trifluoroacetate;
 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-ethylbenzamide;
- N-(4-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- 10 N-[3-({2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)phenyl]acetamide;
 N-(4-{[2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- 15 4-(1-(1,2,3,4-Tetrahydro-7-isoquinoliny)-6-{[4-(trifluoromethyl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furan-3-amine;
 4-[6-[(4-Fluorophenyl)oxy]-1-(4-{[2-(methylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-furan-3-amine;
 N-[3-({2-(4-Amino-furazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)phenyl]acetamide;
- 20 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[(4-methyl-1,3-thiazol-2-yl)methyl]benzamide;
 1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(4-morpholinyl)-1-butanol;
- 25 methyl 3-{[2-(4-Amino-furazan-3-yl)-1-(1H-indazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-(2-oxo-1-pyrrolidinyl)propanamide;
 4-{1-Ethyl-6-[(3-{[(1-methyl-3-piperidinyl)methyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furan-3-amine;
- 30 3-({2-(4-Amino-furazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)benzenesulfonamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)cyclohexanecarboxamide;
- 5 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{[4-(methyloxy)phenyl]methyl}benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(cyclopropylmethyl)benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(1,3-
- 10 benzodioxol-5-ylmethyl)benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-1-butanefulfonamide;
- N-[(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)carbonyl]-beta-alanine;
- 15 4-{1-Ethyl-6-[(3-{[3-(4-morpholinyl)propyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 1,1-Dimethylethyl (3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)carbamate;
- 3-([2-(4-Amino-furazan-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-
- 20 c]pyridin-6-yl]oxy)-N-[2-(4-morpholinyl)ethyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(dimethylamino)phenyl]benzamide;
- 1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-methyl-4-(4-morpholinyl)-1-butanone;
- 25 1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-1-propanone;
- 1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)ethanol;
- 4-[6-[(4-Fluorophenyl)oxy]-1-(2-methyl-1,2,3,4-tetrahydro-7-isoquinoliny)]-1H-
- 30 imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
- 2-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-butanol;

- 3-{[2-(4-Amino-furazan-3-yl)-1-(6-methyl-2-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
 4-{6-[(3-Aminophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 5 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-methyl-N-[3-(1-methyl-4-piperidinyl)propyl]benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{2-[3,5-bis(methyloxy)phenyl]ethyl}benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(dimethylamino)benzamide;
- 10 4-(1-(4-{[2-(Dimethylamino)ethyl]oxy}phenyl)-6-{[3-(methylsulfonyl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
 4-(1-Ethyl-6-{[3-(methyloxy)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
- 15 3-{[2-(4-Amino-furazan-3-yl)-1-(6-methyl-2-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
 4-[1-Ethyl-6-({3-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]phenyl}oxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)-3-(trifluoromethyl)benzamide;
- 20 N-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-methylbenzenesulfonamide;
- 25 Methyl (3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetate;
 N-(5-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-2-methylphenyl)acetamide;
 1-{3-[(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)oxy]propyl}-2-pyrrolidinone;
- 30 (3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetic acid;

- N-(4-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio}phenyl)acetamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-fluorobenzenesulfonamide;
- 5 1-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)ethanone;
- 4-{2-(4-Amino-furazan-3-yl)-6-[(3-aminophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl}phenyl 2-methylpropanoate;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzonitrile;
- 10 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-methylbutanamide;
- 4-({[(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)amino]carbonyl}amino)benzoic acid;
- 15 4-{6-[(4-Aminophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 4-{1-Ethyl-6-[(3-{[2-(4-morpholinyl)ethyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 3-({2-(4-Amino-furazan-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
- 20 3-{[2-(4-Amino-furazan-3-yl)-1-(2-methyl-4-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
- 3-({2-(4-Amino-furazan-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 25 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N-methylacetamide;
- N-(4-{2-(4-Amino-furazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)methanesulfonamide;
- 30 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;

- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(phenyloxy)ethyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-2-methylphenyl)acetamide;
- 5 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(dimethylamino)propyl]-N-methylbenzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-
- 10 (4-morpholinyl)ethyl]benzenesulfonamide;
4-{2-(4-Amino-furazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl}-2-chlorophenol;
4-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy} benzonitrile;
- 15 4-(1-Ethyl-7-{[3-(methyloxy)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy} benzoic acid;
4-{6-[(3,4-Dimethylphenyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-
- 20 amine;
4-{1-[2-(Aminoacetyl)-1,2,3,4-tetrahydro-7-isoquinoliny]-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
4-(1-Ethyl-6-{[3-(1,3-thiazol-5-yl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
- 25 4-(1-Ethyl-6-{[3-(1H-imidazol-1-yl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
4-(1-Ethyl-6-{[3-(1,3-oxazol-5-yl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
4-(1-Ethyl-6-{[3-(4-morpholinyl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-
- 30 furazan-3-amine;
4-(1-Phenyl-6-{[3-(1-piperidiny)carbonyl]phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;

- 4-(6-{[3-(Dimethylamino)phenyl]oxy}-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-
furazan-3-amine;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N,N-
dimethylbenzamide;
- 5 N-(4-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-
yl]oxy}phenyl)acetamide;
- Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(1,3-benzodioxol-5-yl)-1H-imidazo[4,5-
c]pyridin-6-yl]oxy}benzoate;
- 5-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-1,3-
10 dimethyl-1,3-dihydro-2H-benzimidazol-2-one;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-
(ethyloxy)propyl]benzamide;
- 2-[7-{2-(4-Amino-furazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-
1-yl}-3,4-dihydro-2(1H)-isoquinoliny]acetamide;
- 15 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-
6-yl]oxy}benzoate;
- 6-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-3,4-
dihydro-1(2H)-naphthalenone;
- 4-[6-(1H-Benzimidazol-5-yloxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-
20 amine;
- 4-(1-Ethyl-6-{[3-(1-methylethyl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-
furazan-3-amine;
- 4-{1-(3-Chloro-4-{[2-(dimethylamino)ethyl]oxy}phenyl)-6-[(4-fluorophenyl)oxy]-
1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 25 4-{6-[(4-Fluorophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-
amine;
- Methyl 4-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
yl]oxy}benzoate;
- 4-{6-[(3-Nitrophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-
30 amine;
- 3-({2-(4-Amino-furazan-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-
6-yl]oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;

- 3-({2-(4-Amino-furazan-3-yl)-1-[2-(dimethylamino)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
 3-{{2-(4-Amino-furazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}benzoic acid;
- 5 Methyl 3-{{2-(4-amino-furazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}benzoate;
 7-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-4-methyl-2(1H)-quinolinone;
 4-{{2-(4-Amino-furazan-3-yl)-6-[(3-aminophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl}phenyl 4-(methyloxy)benzoate;
- 10 3-({2-(4-Amino-furazan-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)benzoic acid;
 Methyl 3-{{2-(4-amino-furazan-3-yl)-1-(2-methyl-1,3-benzoxazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}benzoate;
- 15 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
 4-{1-Ethyl-6-[(3-{{2-(1-methyl-3-piperidinyl)ethyl}oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 20 4-[1-Ethyl-6-({3-[4-(1-methyl-4-piperidinyl)butyl]phenyl}oxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
 1-(3-{{2-(4-Amino-furazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinoliny)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)ethanone;
- 25 More preferred compounds:
 3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-(4-{{3-(dimethylamino)propyl}oxy}phenyl)benzamide;
 3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-{4-[2-(1-pyrrolidinyl)ethyl]phenyl}benzamide;
- 30 3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-{4-[(dimethylamino)methyl]phenyl}benzamide;

- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{4-[2-(dimethylamino)ethyl]phenyl}benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(dimethylamino)ethyl]oxy}benzamide;
 5 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(1-methyl-4-piperidiny)propyl]benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-[(dimethylamino)methyl]benzamide;
 10 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(diethylamino)ethyl]oxy}benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-({2-[bis(1-methylethyl)amino]ethyl}oxy)benzamide;
 15 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(1-piperidiny)ethyl]oxy}benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-methyl-1-piperazinyl)ethyl]benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
 20 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(4-{[2-(4-morpholinyl)ethyl]oxy}phenyl)benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(1-pyrrolidiny)ethyl]oxy}benzamide;
 25 4-(Aminomethyl)-N-(3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-(3-pyridiny)propanamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-piperidiny)ethyl]benzamide;
 30 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{2-[4-hydroxy-3-(methyloxy)phenyl]ethyl}benzamide;

- 3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[4-(4-morpholinyl)phenyl]benzamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-3-(4-piperidiny)propanamide;
- 5 3-{{2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(1-methyl-4-piperidiny)propyl]benzamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-1-methyl-1H-1,2,3-benzotriazole-5-carboxamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-3-(4-hydroxyphenyl)propanamide;
- 10 3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-(2-oxo-2-phenylethyl)benzamide;
- 1-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-(4-methyl-1-piperazinyl)-4-oxo-1-butanone;
- 15 N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-(4-morpholinylmethyl)benzamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-{{2-(4-morpholinyl)ethyl}oxy}benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide;
- 20 N-[4-(Acetylamino)phenyl]-3-{{2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}benzamide;
- 3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[4-(dimethylamino)phenyl]benzamide;
- 25 N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-3-pyridinecarboxamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-(dimethylamino)butanamide;
- N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-(diethylamino)butanamide;
- 30 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;

- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-hydroxy-2-(4-hydroxyphenyl)ethyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(tetrahydro-2H-pyran-4-yl)ethyl]benzamide;
- 5 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[3-(1-piperidiny)propyl]oxy}benzamide;
- N-[4-(Aminocarbonyl)phenyl]-3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(4-morpholinyl)ethyl]oxy}benzamide;
- 10 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(4-piperidinylmethyl)benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methylamino)butanamide;
- 15 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-hydroxyphenyl)ethyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{4-[(1,1-dioxido-4-thiomorpholinyl)methyl]phenyl}benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(1-
- 20 piperidinyl)propyl]benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- 4-{1-Ethyl-6-[(3-{[4-(1-methyl-4-piperidinyl)butyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 25 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(1H-imidazol-1-yl)benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(4-morpholinyl)butanamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-
- 30 yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[4-(methyloxy)phenyl]benzamide;

- 1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(4-morpholinyl)-1-butanone;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3,4-bis(methyloxy)benzamide;
5 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-6-methyl-3-pyridinecarboxamide;
3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-thiomorpholinyl)ethyl]benzamide;
N-[4-(Aminomethyl)phenyl]-3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1H-
10 imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2,3-dihydro-1-benzofuran-5-carboxamide;
N-[2-(4-Acetyl-1-piperazinyl)ethyl]-3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
15 3-{[2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
N-[3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-5-(trifluoromethyl)phenyl]acetamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
20 yl]oxy}phenyl)urea;
3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-hydroxybenzamide;
25 3-{[2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(4-morpholinyl)benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-
30 imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)benzamide;
N-(3-{[1-{4-[(2-Aminoethyl)oxy]phenyl}-2-(4-amino-furazan-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;

- N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-6-methyl-3-pyridinecarboxamide;
- N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-methyl-1,3-thiazole-5-carboxamide;
- 5 N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(dimethylamino)butanamide;
- N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-([3-(1-piperazinyl)propyl]oxy}benzamide;
- N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-(dimethylamino)-5-pyrimidinecarboxamide;
- 10 3-([2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
- 4-{1-Ethyl-6-([3-([2-(1-methyl-4-piperidinyl)ethyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl)}-furazan-3-amine;
- 15 3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-furancarboxamide;
- 3-([2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[2-
- 20 (3-pyridinyl)ethyl]benzamide;
- N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-([1-methyl-4-piperidinyl]oxy)benzamide;
- N-(3-([2-(4-Amino-furazan-3-yl)-1-(4-([2-(methylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- 25 N-[3-([2-(4-Amino-furazan-3-yl)-1-[4-([(2S)-1-methyl-2-pyrrolidinyl]methyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl]acetamide;
- N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(dimethylamino)benzamide;
- 30 N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(2-oxo-1-pyrrolidinyl)butanamide;

- N-1-~(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N-3~,N-3~-dimethyl-beta-alaninamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-(methyloxy)acetamide;
- 5 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(1H-imidazol-1-yl)propyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-pyridinyl)ethyl]benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-6-(1H-pyrazol-1-yl)-3-pyridinecarboxamide;
- 10 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(1-pyrrolidinyl)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(1-oxido-4-thiomorpholinyl)ethyl]benzamide;
- 15 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-{[2-(1-piperazinyl)ethyl]oxy}benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(1-piperidinyl)benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)benzamide;
- 20 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(diethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- 25 4-{1-Ethyl-6-[(3-{[3-(1-methyl-4-piperidinyl)propyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenol;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(ethyloxy)benzamide;
- 30 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(1,4-dioxan-2-ylmethyl)benzamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-methyl-3-pyridinecarboxamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)butanamide;
- 5 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-methyl-3,4-dihydro-2H-1,4-benzoxazine-7-carboxamide;
4-{2-(4-Amino-furazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl}phenol;
3-{[2-(4-Amino-furazan-3-yl)-1-(1H-benzimidazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 10 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(tetrahydro-2-furanylmethyl)benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(dimethylamino)propyl]benzamide;
- 15 3-{[2-(4-Amino-furazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(dimethylamino)butanamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-fluorobenzamide;
- 20 4-(Aminomethyl)-N-(3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-6-{[2-(4-morpholinyl)ethyl]oxy}-3-pyridinecarboxamide;
- 25 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(1-piperidinyl)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-chloro-4-(methoxy)benzamide;
- 30 3-{[2-(4-Amino-furazan-3-yl)-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide;

- 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(1-pyrrolidinyl)propyl]benzamide;
N-(3-{{2-(4-Amino-furazan-3-yl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-{{2-(4-morpholinyl)ethyl}oxy}benzamide;
- 5 N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-3-fluoro-4-(methyloxy)benzamide;
3-{{2-(4-Amino-furazan-3-yl)-1-(cyclopropylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-3-(methyloxy)benzamide;
- 10 3-{{2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-3-(3-hydroxyphenyl)propanamide;
- 15 N-(3-{{2-(4-Amino-furazan-3-yl)-1-(4-{{2-(dimethylamino)ethyl}oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)acetamide;
4-[6-[(4-Fluorophenyl)oxy]-1-(1,2,3,4-tetrahydro-7-isoquinoliny)]-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
3-{{2-(4-Amino-furazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinoliny)]-1H-
- 20 imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
3-{{2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-6-[(2,2,2-trifluoroethyl)oxy]-3-pyridinecarboxamide;
- 25 N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-N'-methylurea;
3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(4-morpholinyl)propyl]benzamide;
N-(3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-{{2-(4-morpholinyl)ethyl}oxy}benzamide;
- 30 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[4-(methyloxy)phenyl]benzamide;

- 4-(6-{[3-Amino-5-(trifluoromethyl)phenyl]oxy}-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-1-methyl-4-piperidinecarboxamide;
- 5 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(1-pyrrolidinyl)ethyl]benzamide;
- 3-({2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(3-amino-3-oxopropyl)benzamide;
- 10 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)methanesulfonamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(4-pyridinylmethyl)benzamide;
- 15 N'-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N,N-dimethylsulfamide;
- Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(1H-benzimidazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
- N-{3-[(2-(4-Amino-furazan-3-yl)-1-{4-[(cyanomethyl)oxy]phenyl}-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl}acetamide;
- 20 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(2-pyridinyl)ethyl]benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N'-methylurea;
- 25 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(1,1-dioxido-4-thiomorpholinyl)ethyl]benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 30 4-{1-Ethyl-6-[(3-{[(1-methyl-4-piperidinyl)methyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)pyrazolo[1,5-a]pyridine-3-carboxamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
5 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(dimethylamino)ethyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(3,5-dimethyl-1H-pyrazol-1-yl)benzamide;
3-([2-(4-Amino-furazan-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-
10 c]pyridin-6-yl]oxy)-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)methanesulfonamide;
3-{[2-(4-Amino-furazan-3-yl)-1-(4-fluorophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
15 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-1-methyl-4-piperidinecarboxamide;
1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)ethanone;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
20 yl]oxy}phenyl)-4-cyanobenzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-(1H-indazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N'-(phenylmethyl)urea;
25 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(1-methyl-1H-pyrrol-2-yl)ethyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(2-oxo-1-pyrrolidinyl)butanamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(4-morpholinyl)ethyl]oxy}phenyl)-1H-
30 imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[4-(dimethylamino)phenyl]benzamide;

- 3-([2-(4-Amino-furazan-3-yl)-1-(4-piperidiny)]-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 4-[6-(1H-Benzimidazol-4-yloxy)-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
- 5 N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)phenyl)-2-methylpropanamide;
- 3-([2-(4-Amino-furazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[2-(4-morpholinyl)ethyl]benzamide;
- N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)phenyl)methanesulfonamide;
- 10 3-([2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[2-(4-morpholinyl)ethyl]benzamide;
- N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)phenyl)-2-(methyloxy)-3-pyridinecarboxamide;
- 15 N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)phenyl)-4-morpholinecarboxamide;
- N'-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)phenyl)-N,N-dimethylsulfamide;
- N-[2-(Acetyl amino)ethyl]-3-([2-(4-amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)benzamide;
- 20 3-([2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[2-(methyloxy)ethyl]benzamide;
- 3-([2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-(2-cyanoethyl)benzamide;
- 25 3-([2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl]oxy)-N-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]benzamide;
- 4-(1-Ethyl-6-[3-(methylsulfonyl)phenyl]oxy)-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
- N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)phenyl)-4-chloro-2-pyridinecarboxamide;
- 30 N-(3-([2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy)phenyl)-4-(trifluoromethyl)-3-pyridinecarboxamide;

- N'-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N,N-dimethylsulfamide;
 4-{6-[(3-Aminophenyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 5 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[(1,5-dimethyl-1H-pyrazol-4-yl)methyl]benzamide;
 N-(3-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-methylpropanamide;
- 10 N-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-(4-morpholinyl)propanamide;
 4-[1-Ethyl-6-({3-[(1E)-3-(4-methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]phenyl}oxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
- 15 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N'-phenylurea;
 3-{[2-(4-Amino-furazan-3-yl)-1-(1,3-benzodioxol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
 4-{1-[4-(Aminomethyl)phenyl]-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 20 2-yl}-furazan-3-amine;
 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoic acid;
 N-(5-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-2-chlorophenyl)acetamide;
- 25 4-{1-(2,3-Dihydro-1H-isoindol-5-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-methylbenzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzamide;
- 30 3-{[2-(4-Amino-furazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;

- 4-{6-[(3-{[3-(4-Acetyl-1-piperazinyl)propyl]oxy}phenyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-1-methyl-1H-imidazole-2-carboxamide;
- 5 3-({2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide trifluoroacetate;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-ethylbenzamide;
- N-(4-{[2-(4-Amino-furazan-3-yl)-1-(4-{[2-(dimethylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- 10 N-[3-({2-(4-Amino-furazan-3-yl)-1-[2-(methyloxy)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)phenyl]acetamide;
- N-(4-{[2-(4-Amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)acetamide;
- 15 4-(1-(1,2,3,4-Tetrahydro-7-isoquinoliny)-6-{[4-(trifluoromethyl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
- 4-[6-[(4-Fluorophenyl)oxy]-1-(4-{[2-(methylamino)ethyl]oxy}phenyl)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
- N-[3-({2-(4-Amino-furazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)phenyl]acetamide;
- 20 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[(4-methyl-1,3-thiazol-2-yl)methyl]benzamide;
- 1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(4-morpholiny)-1-butanol;
- 25 methyl 3-{[2-(4-Amino-furazan-3-yl)-1-(1H-indazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-(2-oxo-1-pyrrolidinyl)propanamide;
- 4-{1-Ethyl-6-[(3-{[(1-methyl-3-piperidinyl)methyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 30 3-({2-(4-Amino-furazan-3-yl)-1-[3-(methyloxy)propyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;

- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-(methyloxy)benzenesulfonamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)cyclohexanecarboxamide;
- 5 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-{[4-(methyloxy)phenyl]methyl}benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(cyclopropylmethyl)benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-(1,3-
10 benzodioxol-5-ylmethyl)benzamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-1-butanefulfonamide;
- N-[(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)carbonyl]-beta-alanine;
- 15 4-{1-Ethyl-6-[(3-{[3-(4-morpholinyl)propyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
- 1,1-Dimethylethyl (3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)carbamate;
- 3-({2-(4-Amino-furazan-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-
20 c]pyridin-6-yl]oxy)-N-[2-(4-morpholinyl)ethyl]benzamide;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(dimethylamino)phenyl]benzamide;
- 1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-methyl-4-(4-morpholinyl)-1-butanone;
- 25 1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-1-propanone;
- 1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)ethanol;
- 4-[6-[(4-Fluorophenyl)oxy]-1-(2-methyl-1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-
30 imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
- 2-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-2-butanol;

- 3-{{2-(4-Amino-furazan-3-yl)-1-(6-methyl-2-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
 4-{{6-[(3-Aminophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
 5 3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-methyl-N-[3-(1-methyl-4-piperidinyl)propyl]benzamide;
 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-{2-[3,5-bis(methyloxy)phenyl]ethyl}benzamide;
 N-(3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-(dimethylamino)benzamide;
 10 4-(1-(4-{{2-(Dimethylamino)ethyl}oxy}phenyl)-6-{{3-(methylsulfonyl)phenyl}oxy})-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
 4-(1-Ethyl-6-{{3-(methyloxy)phenyl}oxy})-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
 15 3-{{2-(4-Amino-furazan-3-yl)-1-(6-methyl-2-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
 4-[1-Ethyl-6-((3-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]phenyl)oxy))-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
 N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-(methyloxy)-3-(trifluoromethyl)benzamide;
 20 N-(3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-(methyloxy)benzamide;
 N-(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)-4-methylbenzenesulfonamide;
 25 Methyl (3-{{2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)acetate;
 N-(5-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}-2-methylphenyl)acetamide;
 1-{{3-[(3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)oxy]propyl}-2-pyrrolidinone;
 30 (3-{{2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl}oxy}phenyl)acetic acid;

- N-(4-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio}phenyl)acetamide;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-4-fluorobenzenesulfonamide;
- 5 1-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)ethanone;
- 4-{2-(4-Amino-furazan-3-yl)-6-[(3-aminophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl}phenyl 2-methylpropanoate;
- 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzonitrile;
- 10 N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-3-methylbutanamide;
- 4-({[(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)amino]carbonyl}amino)benzoic acid;
- 15 4-{6-[(4-Aminophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 4-{1-Ethyl-6-[(3-{[2-(4-morpholinyl)ethyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 3-({2-(4-Amino-furazan-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(4-methyl-1-piperazinyl)propyl]benzamide;
- 20 3-{[2-(4-Amino-furazan-3-yl)-1-(2-methyl-4-pyridinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
- 3-({2-(4-Amino-furazan-3-yl)-1-[4-(trifluoromethyl)phenyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
- 25 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(4-piperidinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
- N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)-N-methylacetamide;
- N-(4-{2-(4-Amino-furazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl}phenyl)methanesulfonamide;
- 30 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;

- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(phenyloxy)ethyl]benzamide;
N-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-2-methylphenyl)acetamide;
- 5 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-(dimethylamino)propyl]-N-methylbenzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide;
- 10 4-{2-(4-Amino-furazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl}-2-chlorophenol;
4-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzonitrile;
- 15 4-(1-Ethyl-7-{[3-(methyloxy)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoic acid;
4-{6-[(3,4-Dimethylphenyl)oxy]-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-
- 20 amine;
4-{1-[2-(Aminoacetyl)-1,2,3,4-tetrahydro-7-isoquinolinyl]-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
4-(1-Ethyl-6-{[3-(1,3-thiazol-5-yl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
- 25 4-(1-Ethyl-6-{[3-(1H-imidazol-1-yl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
4-(1-Ethyl-6-{[3-(1,3-oxazol-5-yl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;
4-(1-Ethyl-6-{[3-(4-morpholinyl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-
- 30 furazan-3-amine;
4-(1-Phenyl-6-{[3-(1-piperidinylcarbonyl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-furazan-3-amine;

- 4-(6-{[3-(Dimethylamino)phenyl]oxy}-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl)-
furazan-3-amine;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N,N-
dimethylbenzamide;
- 5 N-(4-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-
yl]oxy}phenyl)acetamide;
- Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(1,3-benzodioxol-5-yl)-1H-imidazo[4,5-
c]pyridin-6-yl]oxy}benzoate;
- 5-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-1,3-
10 dimethyl-1,3-dihydro-2H-benzimidazol-2-one;
- 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[3-
(ethyloxy)propyl]benzamide;
- 2-[7-{2-(4-Amino-furazan-3-yl)-6-[(4-fluorophenyl)oxy]-1H-imidazo[4,5-c]pyridin-
1-yl}-3,4-dihydro-2(1H)-isoquinoliny]acetamide;
- 15 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(4-bromophenyl)-1H-imidazo[4,5-c]pyridin-
6-yl]oxy}benzoate;
- 6-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-3,4-
dihydro-1(2H)-naphthalenone;
- 4-[6-(1H-Benzimidazol-5-yloxy)-1-ethyl-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-
20 amine;
- 4-(1-Ethyl-6-{[3-(1-methylethyl)phenyl]oxy}-1H-imidazo[4,5-c]pyridin-2-yl)-
furazan-3-amine;
- 4-{1-(3-Chloro-4-{[2-(dimethylamino)ethyl]oxy}phenyl)-6-[(4-fluorophenyl)oxy]-
1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
- 25 4-{6-[(4-Fluorophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-
amine;
- Methyl 4-{[2-(4-amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-
yl]oxy}benzoate;
- 4-{6-[(3-Nitrophenyl)oxy]-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-
30 amine;
- 3-({2-(4-Amino-furazan-3-yl)-1-[2-(4-morpholiny)ethyl]-1H-imidazo[4,5-c]pyridin-
6-yl]oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;

- 3-({2-(4-Amino-furazan-3-yl)-1-[2-(dimethylamino)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)-N-[3-(2-oxo-1-pyrrolidinyl)propyl]benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoic acid;
 5 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
 7-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-4-methyl-2(1H)-quinolinone;
 4-{2-(4-Amino-furazan-3-yl)-6-[(3-aminophenyl)oxy]-1H-imidazo[4,5-c]pyridin-1-yl}phenyl 4-(methoxy)benzoate;
 10 3-({2-(4-Amino-furazan-3-yl)-1-[2-(4-morpholinyl)ethyl]-1H-imidazo[4,5-c]pyridin-6-yl}oxy)benzoic acid;
 Methyl 3-{[2-(4-amino-furazan-3-yl)-1-(2-methyl-1,3-benzoxazol-5-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate;
 15 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
 3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzamide;
 4-{1-Ethyl-6-[(3-{[2-(1-methyl-3-piperidinyl)ethyl]oxy}phenyl)oxy]-1H-imidazo[4,5-c]pyridin-2-yl}-furazan-3-amine;
 20 4-[1-Ethyl-6-({3-[4-(1-methyl-4-piperidinyl)butyl]phenyl}oxy)-1H-imidazo[4,5-c]pyridin-2-yl]-furazan-3-amine;
 1-(3-{[2-(4-Amino-furazan-3-yl)-1-(1,2,3,4-tetrahydro-7-isoquinolinyl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}phenyl)ethanone;

25

Inhibitors of ROCKs have been suggested for use in the treatments of a variety of diseases. They include cardiovascular diseases such as hypertension, chronic and congestive heart failure, ischemic angina, cardiac hypertrophy and fibrosis, restenosis, chronic renal failure and atherosclerosis. In addition, because of its muscle relaxing properties, it is also suitable for asthma, male erectile dysfunctions, female sexual dysfunction and over-active bladder syndrome. ROCK inhibitors have been shown to possess anti-inflammatory properties. Thus they can

30

be used as treatment for neuroinflammatory diseases such as stroke, multiple sclerosis, Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and inflammatory pain, as well as other inflammatory diseases such as rheumatoid arthritis, irritable bowel syndrome, inflammatory bowel disease, and Crohn's diseases. In addition, based on their neurite outgrowth inducing effects, ROCK inhibitors could be useful drugs for neuronal regeneration, inducing new axonal growth and axonal rewiring across lesions within the CNS. ROCK inhibitors are therefore likely to be useful for regenerative (recovery) treatment of CNS disorders such as spinal cord injury, acute neuronal injury (stroke, traumatic brain injury), Parkinson's disease, Alzheimer's disease and other neurodegenerative disorders. Since ROCK inhibitors reduce cell proliferation and cell migration, they could be useful in treating cancer and tumor metastasis. Further more, there is evidence suggesting that ROCK inhibitors suppress cytoskeletal rearrangement upon virus invasion, thus they also have potential therapeutic value in anti-viral and anti-bacterial applications. ROCK inhibitors are also useful for the treatment of insulin resistance and diabetes.

Preferably ROCK inhibitors are useful for the treatment of hypertension, chronic and congestive heart failure, ischemic angina, asthma, male erectile dysfunction, female sexual dysfunction, stroke, inflammatory bowel diseases, spinal cord injury, glaucoma and tumor metastasis.

More preferably ROCK inhibitors are useful for the treatment of hypertension, chronic and congestive heart failure and ischemic angina.

As used herein, the term "effective amount" means that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought, for instance, by a researcher or clinician. Furthermore, the term "therapeutically effective amount" means any amount which, as compared to a corresponding subject who has not received such amount, results in improved treatment, healing, prevention, or amelioration of a disease, disorder, or side effect, or a decrease in the rate of advancement of a disease or disorder. The term also includes within its scope amounts effective to enhance normal physiological function.

As used herein, the term “optionally” means that the subsequently described event(s) may or may not occur, and includes both event(s), which occur, and events that do not occur.

As used herein, the term “physiologically functional derivative” refers to any
5 pharmaceutically acceptable derivative of a compound of the present invention, for example, an ester or an amide, which upon administration to a mammal is capable of providing (directly or indirectly) a compound of the present invention or an active metabolite thereof. Such derivatives are clear to those skilled in the art, without undue experimentation, and with reference to the teaching of Burger’s Medicinal
10 Chemistry And Drug Discovery, 5th Edition, Vol 1: Principles and Practice, which is incorporated herein by reference to the extent that it teaches physiologically functional derivatives.

As used herein, the term “solvate” refers to a complex of variable stoichiometry formed by a solute (in this invention, a compound of formula (I) or a
15 salt or physiologically functional derivative thereof) and a solvent. Such solvents for the purpose of the invention may not interfere with the biological activity of the solute. Examples of suitable solvents include, but are not limited to, water, methanol, ethanol and acetic acid. Preferably the solvent used is a pharmaceutically acceptable solvent. Examples of suitable pharmaceutically acceptable solvents include, without
20 limitation, water, ethanol and acetic acid. Most preferably the solvent used is water.

As used herein, the term “substituted” refers to substitution with the named substituent or substituents, multiple degrees of substitution being allowed unless otherwise stated.

Certain of the compounds described herein may contain one or more chiral
25 atoms, or may otherwise be capable of existing as two enantiomers. The compounds of this invention include mixtures of enantiomers as well as purified enantiomers or enantiomerically enriched mixtures. Also included within the scope of the invention are the individual isomers of the compounds represented by formula (I) above as well as any wholly or partially equilibrated mixtures thereof. The present invention also
30 covers the individual isomers of the compounds represented by the formulas above as mixtures with isomers thereof in which one or more chiral centers are inverted. Also,

it is understood that any tautomers and mixtures of tautomers of the compounds of formula (I) are included within the scope of the compounds of formula (I).

Typically, the salts of the present invention are pharmaceutically acceptable salts. Salts encompassed within the term "pharmaceutically acceptable salts" refer to non-toxic salts of the compounds of this invention. Salts of the compounds of the present invention may comprise acid addition salts derived from a nitrogen on a substituent in the compound of formula (I). Representative salts include the following salts: acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride, edetate, edisylate, estolate, esylate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, hydroxynaphthoate, iodide, isethionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylbromide, methylnitrate, methylsulfate, monopotassium maleate, mucate, napsylate, nitrate, N-methylglucamine, oxalate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, potassium, salicylate, sodium, stearate, subacetate, succinate, tannate, tartrate, teoclate, tosylate, triethiodide, trimethylammonium and valerate. Other salts, which are not pharmaceutically acceptable, may be useful in the preparation of compounds of this invention and these form a further aspect of the invention.

While it is possible that, for use in therapy, therapeutically effective amounts of a compound of formula (I), as well as salts, solvates and physiological functional derivatives thereof, may be administered as the raw chemical, it is possible to present the active ingredient as a pharmaceutical composition. Accordingly, the invention further provides pharmaceutical compositions, which include therapeutically effective amounts of compounds of the formula (I) and salts, solvates and physiological functional derivatives thereof, and one or more pharmaceutically acceptable carriers, diluents, or excipients. The compounds of the formula (I) and salts, solvates and physiological functional derivatives thereof, are as described above. The carrier(s), diluent(s) or excipient(s) must be acceptable in the sense of being compatible with the other ingredients of the formulation and not deleterious to the recipient thereof. In accordance with another aspect of the invention there is also

provided a process for the preparation of a pharmaceutical formulation including admixing a compound of the formula (I), or salts, solvates and physiological functional derivatives thereof, with one or more pharmaceutically acceptable carriers, diluents or excipients.

5 Pharmaceutical formulations may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Such a unit may contain, for example, 0.5mg to 1g, preferably 1mg to 700mg, more preferably 5mg to 100mg of a compound of the formula (I), depending on the condition being treated, the route of administration and the age, weight and condition of the patient, or pharmaceutical
10 formulations may be presented in unit dose forms containing a predetermined amount of active ingredient per unit dose. Preferred unit dosage formulations are those containing a daily dose or sub-dose, as herein above recited, or an appropriate fraction thereof, of an active ingredient. Furthermore, such pharmaceutical formulations may be prepared by any of the methods well known in the pharmacy
15 art.

Pharmaceutical formulations may be adapted for administration by any appropriate route, for example by the oral (including buccal or sublingual), rectal, nasal, topical (including buccal, sublingual or transdermal), vaginal or parenteral (including subcutaneous, intramuscular, intravenous or intradermal) route. Such
20 formulations may be prepared by any method known in the art of pharmacy, for example by bringing into association the active ingredient with the carrier(s) or excipient(s).

Pharmaceutical formulations adapted for oral administration may be presented as discrete units such as capsules or tablets; powders or granules; solutions
25 or suspensions in aqueous or non-aqueous liquids; edible foams or whips; or oil-in-water liquid emulsions or water-in-oil liquid emulsions.

For instance, for oral administration in the form of a tablet or capsule, the active drug component can be combined with an oral, non-toxic pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like. Powders are
30 prepared by comminuting the compound to a suitable fine size and mixing with a similarly comminuted pharmaceutical carrier such as an edible carbohydrate, as, for

example, starch or mannitol. Flavoring, preservative, dispersing and coloring agent can also be present.

Capsules are made by preparing a powder mixture, as described above, and filling formed gelatin sheaths. Glidants and lubricants such as colloidal silica, talc, magnesium stearate, calcium stearate or solid polyethylene glycol can be added to the powder mixture before the filling operation. A disintegrating or solubilizing agent such as agar-agar, calcium carbonate or sodium carbonate can also be added to improve the availability of the medicament when the capsule is ingested.

Moreover, when desired or necessary, suitable binders, lubricants, disintegrating agents and coloring agents can also be incorporated into the mixture. Suitable binders include starch, gelatin, natural sugars such as glucose or beta-lactose, corn sweeteners, natural and synthetic gums such as acacia, tragacanth or sodium alginate, carboxymethylcellulose, polyethylene glycol, waxes and the like. Lubricants used in these dosage forms include sodium oleate, sodium stearate, magnesium stearate, sodium benzoate, sodium acetate, sodium chloride and the like. Disintegrators include, without limitation, starch, methyl cellulose, agar, bentonite, xanthan gum and the like. Tablets are formulated, for example, by preparing a powder mixture, granulating or slugging, adding a lubricant and disintegrant and pressing into tablets. A powder mixture is prepared by mixing the compound, suitably comminuted, with a diluent or base as described above, and optionally, with a binder such as carboxymethylcellulose, an aliginat, gelatin, or polyvinyl pyrrolidone, a solution retardant such as paraffin, a resorption accelerator such as a quaternary salt and/or an absorption agent such as bentonite, kaolin or dicalcium phosphate. The powder mixture can be granulated by wetting with a binder such as syrup, starch paste, acadia mucilage or solutions of cellulosic or polymeric materials and forcing through a screen. As an alternative to granulating, the powder mixture can be run through the tablet machine and the result is imperfectly formed slugs broken into granules. The granules can be lubricated to prevent sticking to the tablet forming dies by means of the addition of stearic acid, a stearate salt, talc or mineral oil. The lubricated mixture is then compressed into tablets. The compounds of the present invention can also be combined with a free flowing inert carrier and compressed into tablets directly without going through the granulating or slugging

steps. A clear or opaque protective coating consisting of a sealing coat of shellac, a coating of sugar or polymeric material and a polish coating of wax can be provided. Dyestuffs can be added to these coatings to distinguish different unit dosages.

Oral fluids such as solution, syrups and elixirs can be prepared in dosage unit
5 form so that a given quantity contains a predetermined amount of the compound. Syrups can be prepared by dissolving the compound in a suitably flavored aqueous solution, while elixirs are prepared through the use of a non-toxic alcoholic vehicle. Suspensions can be formulated by dispersing the compound in a non-toxic vehicle. Solubilizers and emulsifiers such as ethoxylated isostearyl alcohols and polyoxy
10 ethylene sorbitol ethers, preservatives, flavor additive such as peppermint oil or natural sweeteners or saccharin or other artificial sweeteners, and the like can also be added.

Where appropriate, dosage unit formulations for oral administration can be microencapsulated. The formulation can also be prepared to prolong or sustain the
15 release as for example by coating or embedding particulate material in polymers, wax or the like.

The compounds of formula (I), and salts, solvates and physiological functional derivatives thereof, can also be administered in the form of liposome delivery systems, such as small unilamellar vesicles, large unilamellar vesicles and
20 multilamellar vesicles. Liposomes can be formed from a variety of phospholipids, such as cholesterol, stearylamine or phosphatidylcholines.

The compounds of formula (I) and salts, solvates and physiological functional derivatives thereof may also be delivered by the use of monoclonal antibodies as individual carriers to which the compound molecules are coupled. The compounds
25 may also be coupled with soluble polymers as targetable drug carriers. Such polymers can include polyvinylpyrrolidone, pyran copolymer, polyhydroxypropylmethacrylamide -phenol, polyhydroxyethylaspartamidephenol, or polyethyleneoxidepolylysine substituted with palmitoyl residues. Furthermore, the compounds may be coupled to a class of biodegradable polymers useful in achieving
30 controlled release of a drug, for example, polylactic acid, polyepsilon caprolactone, polyhydroxy butyric acid, polyorthoesters, polyacetals, polydihydropyrans, polycyanoacrylates and cross-linked or amphipathic block copolymers of hydrogels.

Pharmaceutical formulations adapted for transdermal administration may be presented as discrete patches intended to remain in intimate contact with the epidermis of the recipient for a prolonged period of time. For example, the active ingredient may be delivered from the patch by iontophoresis as generally described
5 in Pharmaceutical Research, 3(6), 318 (1986).

Pharmaceutical formulations adapted for topical administration may be formulated as ointments, creams, suspensions, lotions, powders, solutions, pastes, gels, sprays, aerosols or oils.

For treatments of the eye or other external tissues, for example mouth and
10 skin, the formulations are preferably applied as a topical ointment or cream. When formulated in an ointment, the active ingredient may be employed with either a paraffinic or a water-miscible ointment base. Alternatively, the active ingredient may be formulated in a cream with an oil-in-water cream base or a water-in-oil base.

Pharmaceutical formulations adapted for topical administrations to the eye
15 include eye drops wherein the active ingredient is dissolved or suspended in a suitable carrier, especially an aqueous solvent.

Pharmaceutical formulations adapted for topical administration in the mouth include lozenges, pastilles and mouth washes.

Pharmaceutical formulations adapted for rectal administration may be
20 presented as suppositories or as enemas.

Pharmaceutical formulations adapted for nasal administration wherein the carrier is a solid include a coarse powder having a particle size for example in the range 20 to 500 microns which is administered in the manner in which snuff is taken, i.e. by rapid inhalation through the nasal passage from a container of the powder held
25 close up to the nose. Suitable formulations wherein the carrier is a liquid, for administration as a nasal spray or as nasal drops, include aqueous or oil solutions of the active ingredient.

Pharmaceutical formulations adapted for administration by inhalation include fine particle dusts or mists, which may be generated by means of various types of
30 metered, dose pressurised aerosols, nebulizers or insufflators.

Pharmaceutical formulations adapted for vaginal administration may be presented as pessaries, tampons, creams, gels, pastes, foams or spray formulations.

Pharmaceutical formulations adapted for parenteral administration include aqueous and non-aqueous sterile injection solutions which may contain anti-oxidants, buffers, bacteriostats and solutes which render the formulation isotonic with the blood of the intended recipient; and aqueous and non-aqueous sterile suspensions
5 which may include suspending agents and thickening agents. The formulations may be presented in unit-dose or multi-dose containers, for example sealed ampoules and vials, and may be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example water for injections, immediately prior to use. Extemporaneous injection solutions and suspensions may be prepared
10 from sterile powders, granules and tablets.

It should be understood that in addition to the ingredients particularly mentioned above, the formulations may include other agents conventional in the art having regard to the type of formulation in question, for example those suitable for oral administration may include flavouring agents.

15 A therapeutically effective amount of a compound of the present invention will depend upon a number of factors including, for example, the age and weight of the human or other animal, the precise condition requiring treatment and its severity, the nature of the formulation, and the route of administration, and will ultimately be at the discretion of the attendant physician or veterinarian. However, an effective
20 amount of a compound of formula (I) for the treatment of neoplastic growth, for example colon or breast carcinoma, will generally be in the range of 0.1 to 100 mg/kg body weight of recipient (mammal) per day and more usually in the range of 1 to 10 mg/kg body weight per day. Thus, for a 70kg adult mammal, the actual amount per day would usually be from 70 to 700 mg and this amount may be given
25 in a single dose per day or more usually in a number (such as two, three, four, five or six) of sub-doses per day such that the total daily dose is the same. An effective amount of a salt or solvate, or physiologically functional derivative thereof, may be determined as a proportion of the effective amount of the compound of formula (I) per se. It is envisaged that similar dosages would be appropriate for treatment of the
30 other conditions referred to above.


The compounds of this invention may be made by a variety of methods, including standard chemistry. Any previously defined variable will continue to have

the previously defined meaning unless otherwise indicated. Illustrative general synthetic methods are set out below and then specific compounds of the invention are prepared in the Working Examples.


5 Compounds of general formula (I) may be prepared by methods known in the art of organic synthesis as set forth in part by the following synthesis schemes. In all of the schemes described below, it is well understood that protecting groups for sensitive or reactive groups are employed where necessary in accordance with general principles of chemistry. Protecting groups are manipulated according to standard methods of organic synthesis (T. W. Green and P. G. M. Wuts (1991)
10 Protecting Groups in Organic Synthesis, John Wiley & Sons). These groups are removed at a convenient stage of the compound synthesis using methods that are readily apparent to those skilled in the art. The selection of processes as well as the reaction conditions and order of their execution shall be consistent with the preparation of compounds of Formula (I).

15 Compounds with the general structure 8 can be prepared according to the procedure described in Scheme 1. Treatment of an appropriately substituted pyridine derivative 1 with potassium *t*-butoxide and *t*-butyl hydroperoxide provides the pyridone 2 which can be chlorinated and the resulting dichloride treated with an amine to give the aminopyridine 3. Displacement of the second chloride with a
20 sodium salt of an alcohol (or phenol) or thiol (or thiophenol), followed by reduction provides structure 5, which can then be coupled to cyanoacetic acid with a variety of coupling agents to provide the corresponding cyanoacetamide 5a. This amide can then be dehydrated with glacial acetic acid to give the azabenzimidazole 6. Alternatively, the diamine 5 can be heated with ethyl cyanoacetate to provide 6
25 directly. The nitrile 6 can be transformed into the oxime 7 by treatment with nitrous acid and then further elaborated to the aminofurazan structure 8 by treatment with hydroxylamine and base either in one step or in a two step process where the intermediate 7a is isolated.


Scheme 1.




- 5 One can further manipulate appropriately substituted compounds 8, an example of which is shown in Scheme 2. The methyl ether **6b** is cleaved with boron tribromide to provide the phenol **9**, which may be alkylated under a variety of conditions to provide the ethers **10**.

Scheme 2.

Compounds of the general structure **17** can be formed according to Scheme 3. Oxidation of 4-methoxy-3-nitro pyridine (**11**) with *t*-butyl hydroperoxide and potassium *t*-butoxide followed by bromination provides 2,4-dibromo-5-nitro-pyridine (**12**) which can be reacted with an amine to provide structure **13**. Reduction, followed by imidazole formation and aminofurazan formation, analogous to Scheme 1 above, provides the bromides **17**.

Scheme 3.

- The bromide **17** can then be transformed into a number of groups as shown in Scheme 4. Alkylamines such as **18** can be formed by treatment with a copper salt and base, whereas aliphatic amines such as **19** can be formed by a palladium-catalyzed amination. Aliphatic and aromatic thiols such as **20** can also be formed under palladium catalysis. Phenolic compounds such as **21** can be formed by treating structures **17** and a phenol with a copper salt, base and a ligand. Related analogs with a carbon tether can be prepared from bromide **17** and the appropriate organozinc reagent in the presence of a palladium catalyst.
- 10 Scheme 4.**




Examples

- The following examples are intended to be illustrative only and not limiting in any way:

Example 1

***N*-(3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetamide**



5 Step 1. 4-Chloro-3-nitropyridine

To a suspension of 3-nitro-4-pyridinol (20 g, 143 mmol) in toluene (300 mL) was added phosphorous oxychloride (65.7g, 429mmol) at 0 °C. The resulting mixture was warmed to room temperature, then heated to reflux (110 °C) for 16 hours. After cooling to rt, the solvent was removed *in vacuo* and the residue was poured on ice,
10 then basified with K₂CO₃ to pH ≈ 10. The mixture was extracted with ethyl acetate and the organic phase was washed twice with water, followed by once with brine before concentrating to a brown oil which solidified on standing (22.5g, 99%). MS (ES+) *m/e* 159 [M+H]⁺.

15 Step 2. 4-Chloro-2-hydroxy-5-nitropyridine

THF (500 mL) was cooled to -78 °C and anhydrous NH₃ (~200 mL) was condensed into the THF. Potassium *t*-butoxide (71.0 g, 630 mmol) was added and the mixture was allowed to warm to ~ -35 °C. The product from Step 1 (40.0 g, 250 mmol) was cooled to 0 °C in THF (200 mL) and a solution of *t*-BuOOH (5 M in
20 decane, 50 mL, 250 mmol) was added over 5 min. This solution was then added dropwise to the KO*t*-Bu solution prepared above over 1 h, then stirred for 2 h at -35 °C and then carefully quenched with ~50 mL of sat. NH₄Cl solution. The mixture was allowed to vent and warm to rt overnight, then the organics were concentrated and the residue made acidic with NH₄Cl solution and filtered. The solid was washed
25 with cold H₂O and dried to give the title compound as a dark brown solid (35 g, 80 %).

Step 3. 2,4-Dichloro-5-nitropyridine

The product from Step 2 (40.0 g, 229 mmol) was suspended in toluene (300 mL) and POCl₃ (65 mL, 697 mmol) was added over 10 min, then the mixture was heated to reflux for 6 h then cooled to 60 °C and allowed to stir overnight at that temperature. The heterogeneous mixture was cooled and concentrated, the residue was carefully made basic with aq. K₂CO₃ solution and extracted with EtOAc. The organic layers were combined, washed with H₂O and brine, dried (Na₂SO₄), filtered and the filtrate was concentrated to give an oil. The crude oil was passed through a plug of silica gel (50% EtOAc in hexanes) to give the title compound (32.5 g, 74 %) as an orange oil which solidified on standing. MS (ES+) m/e 194 [M+H]⁺.

Step 4. 2-Chloro-5-nitro-N-phenyl-4-pyridinamine

The product of Step 3 (66.5g, 345 mmol) in THF (400 mL) and triethylamine (50.3 mL, 361 mmol) was added, followed by aniline (31.4 mL, 345 mmol) and the reaction mixture was allowed to stir at rt for 18 hours. Water (1.2 L) was added dropwise to the yellow solution and the precipitate formed was filtered, washed with H₂O and Et₂O to give the title compounds as yellow crystals (42.8 g). The filtrate was concentrated to roughly ½ volume and the resulting solid was filtered and washed with H₂O and Et₂O to give additional title compound (18.1 g, 60.9g total, 71%). ¹H NMR (400 MHz, CDCl₃) δ ppm 9.68 (s, 1H), 9.13 (s, 1H), 7.54 (t, 2H, 7.3Hz), 7.42 (t, 1H, 7.3Hz), 7.31 (d, 2H, 7.3Hz), 6.94 (s, 1H). MS (ES+) m/e 250 [M+H]⁺.

Step 5. N-(3-{{5-Nitro-4-(phenylamino)-2-pyridinyl}oxy}phenyl)acetamide

Sodium hydride (60% dispersion in oil, 16.24 g, 406 mmol) was suspended in DMF (800 mL) and solid N-(3-hydroxyphenyl)acetamide (61.0 g, 406 mol) was added portionwise over 1 h (warming and frothing occurs). After the final addition the product from Step 4 (101.2g, 406 mmol) was added as a solid, portionwise, over 10 min and the resulting mixture was heated to 60 °C overnight. Water (800 mL) was carefully added dropwise to the still warm reaction mixture over 1 h to give a fine yellow precipitate. The mixture was then cooled to 0 °C, filtered and the resulting solid was washed with cold H₂O and hexane to give the title compound (143.3 g,

97%) as a yellow solid. ^1H NMR (400 MHz, DMSO- D_6) δ ppm 10.06 (s, 1H), 9.80 (s, 1H), 8.91 (s, 1H), 7.44-7.49 (m, 3H), 7.37 (dd, 2H, 1.26Hz, 8.6Hz), 7.29-7.33 (m, 3H), 6.76-6.80 (m, 1H), 6.22 (s, 1H), 2.04 (s, 3H). MS (ES+) m/e 365 $[\text{M}+\text{H}]^+$.

5 **Step 6. *N*-(3-([5-Amino-4-(phenylamino)-2-pyridinyl]oxy)phenyl)acetamide**

The product of Step 5 (37.7 g, 103.5 mmol) in MeOH (350 mL) and dichloromethane (350 mL) was hydrogenated for overnight with a balloon of hydrogen gas in the presence of 10% palladium on carbon (3.5 g). After filtration of the catalyst through a pad of Celite, the filtrate was concentrated *in vacuo* to afford
10 the title compound as a crude foam (~35 g, quantitative). ^1H NMR (400 MHz, MeOD) δ ppm 7.56 (s, 1H), 7.39-7.40 (m, 1H), 7.19-7.34 (m, 5H), 7.07-7.11 (m, 1H), 6.73 (dt, 1H, 1.8 Hz, 7.1Hz), 6.48 (s, 1H), 3.32-3.34 (m, 3H), 2.12 (s, 3H). MS (ES+) m/e 335 $[\text{M}+\text{H}]^+$.

15 **Step 7. *N*-(3-[2-(Cyanomethyl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy)phenyl)acetamide**

The product from Step 6 (29.4 g, 88 mmol), cyanoacetic acid (14.9 g, 176 mmol) and EDCI (33.7 g, 176 mmol) were suspended in CH_2Cl_2 (500 mL), Et₃N (49 mL, 352 mmol) was added and the resulting solution was allowed to stir at rt
20 overnight. The reaction mixture was poured into H_2O and extracted with EtOAc. The organic extracts were combined, washed with H_2O and brine, dried (MgSO_4), filtered and the filtrate was concentrated to give a crude oil (~35 g) which was used without purification.

The crude amide from above (35 g, ~88 mmol) was heated to 100 °C for 2h,
25 then concentrated. The residue was made basic with sat. aq. K_2CO_3 and extracted with EtOAc. The organic extracts were combined, washed with H_2O and brine, dried (MgSO_4), filtered and the filtrate was concentrated to give a foam. The foam was triturated with MeOH to give the title compound as a light yellow solid (19.5 g). The mother liquors were combined, concentrate and purified by column
30 chromatography (20%-100% EtOAc in hexane) to give an additional portion of the title compound (2.3 g, 21.8 g total, 65 % over two steps). ^1H NMR (400 MHz, MeOD) δ ppm 8.65 (d, 1H, 0.76Hz), 7.65-7.69 (m, 3H), 7.54-7.57 (m, 2H), 7.45-7.45

(m, 1H), 7.25-7.33 (m, 2H), 6.78-6.81 (m, 1H), 6.70 (d, 1H, 0.76Hz), 2.11 (s, 3H), 1.31 (s, 2H). MS (ES+) m/e 384 [M+H]⁺.


Step 8. *N*-(3-{[2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetamide

Sodium nitrite (1.9 g, 27.6 mmol) was added portionwise to a solution of the product from Step 7 (10.6 g, 27.6 mmol) in MeOH (150 mL) and 1.2 M aq. HCl (125 mL). After ~10 min a thick slurry formed and the mixture was allowed to stir for an additional 1h, then the precipitate was filtered, washed with H₂O and dried in vacuo to give the desired oxime (10.8 g, 95%) which was used directly in the next step.

The product from above (10.8 g, 26.2 mmol) was suspended in dioxane (100 mL) and Et₃N (20 mL) and hydroxylamine (50% aq. soln., 1.7 mL, 26.2 mmol) was added and the mixture was heated to 110 °C for 48 h. The reaction mixture was cooled, concentrated, partitioned between 1M HCl and EtOAc and extracted with EtOAc. The organic extracts were combined, washed with H₂O and brine, dried (MgSO₄), filtered and the filtrate was concentrated to give a solid which was triturated with MeOH to give the title compound as a tan solid (4.5 g, 40%). ¹H NMR (400 MHz, MeOD) δ ppm 8.84 (s, 1H), 7.65-7.67 (m, 3H), 7.54-7.56 (m, 2H), 7.49-7.50 (m, 1H), 7.30-7.36 (m, 2H), 6.83 (dt, 1H, 2.3Hz, 7.8Hz), 6.70 (d, 1H, 0.8Hz), 2.64-2.65 (m, 3H), 2.12 (s, 3H). MS (ES+) m/e 428 [M+H]⁺.

Example 2

***N*-(3-{[1-{4-[(2-Aminoethyl)oxy]phenyl}-2-(4-amino-furazan-3-yl)-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetamide**



Step 1. 2-Chloro-*N*-(4-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}phenyl)-5-nitro-4-pyridinamine

The product from Example 1, Step 3 (20.0 g, 104 mmol) and triethylamine (17.4 mL, 125 mmol) were dissolved in THF (200 mL) and a solution of 4-[(1,1-dimethylethyl)(dimethyl)silyl]oxy}aniline (25.0 g, 113 mmol) in THF (50 mL) was added and the mixture was allowed to stir at rt overnight. The reaction mixture was poured into water and extracted with EtOAc. The combined organic phases were washed with brine, dried (MgSO₄), filtered and the filtrate was concentrated to give the title compound (37.5 g, 95%) as a yellow oil. MS (ES+) m/e 381 [M+H]⁺.

Step 2. *N*-[3-({4-[(4-Hydroxyphenyl)amino]-5-nitro-2-pyridinyl}oxy)phenyl]acetamide

A solution of 3-acetamidophenol (10.8 g, 72 mmol) in DMF (50 mL) was added dropwise to a slurry of NaH (60% in oil, 2.88 g, 72 mmol) over 1 h. A solution of the product from Step 1 (13.7 g, 36.0 mmol) in DMF (50 mL) was added and the resulting mixture was heated to 60 °C overnight. The reaction mixture was poured into water and extracted with EtOAc. The organic layers were combined, washed with brine, dried (MgSO₄), filtered and the filtrate was concentrated to give an oil which was purified by chromatography (10-100 % EtOAc in hexanes) to give the title compound (4.6 g, 34 %) as an orange solid. MS (ES+) m/e 381 [M+H]⁺.

Step 3. *N*-[3-({5-Amino-4-[(4-hydroxyphenyl)amino]-2-pyridinyl}oxy)phenyl]acetamide

The product of Step 2 (2.9 g, 7.6 mmol) was hydrogenated in methanol (50 mL) in the presence of 5% Pd/C (250 mg) with a balloon of hydrogen overnight. The reaction mixture was filtered through Celite and concentrated to give the title compound (2.1 g, 79%) as a dark orange solid. MS (ES+) m/e 351 [M+H]⁺.

Step 4. *N*-(3-{[2-(cyanomethyl)-1-(4-hydroxyphenyl)-2,3-dihydro-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetamide

The product from Step 3 (2.9 g, 8.3 mmol) and ethyl cyanoacetate (6 mL) were combined and heated to 195 °C in a sealed tube. The reaction mixture was cooled and the crude material was purified by chromatography (0-10% methanol in EtOAc) to give the title compound (2.6 g, 78 %). MS (ES+) m/e 400 [M+H]⁺.

Step 5. *N*-(3-([2-(4-amino-furazan-3-yl)-1-(4-hydroxyphenyl)-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetamide


A solution of the product from Step 4 (2.6 g, 6.5 mmol) in methanol (30 mL),
5 water (20 mL) and 6M HCl (8 mL) was treated with NaNO₂ (670 mg, 9.75 mmol)
portionwise over 10 min then allowed to stir at rt for 1h. The reaction mixture was
poured into water and extracted with EtOAc. The organic phases were combined,
washed with brine, dried (MgSO₄), filtered and the filtrate concentrated to give a
dark solid which was suspended in dioxane (20 mL) and treated with triethylamine (3
10 mL) and NH₂OH (50% aqueous solution, 650 uL) and then heated to 90 °C for 2 h,
then cooled to rt. The reaction mixture was poured into aq. NH₄Cl and extracted
with EtOAc. The organic phases were combined, washed with brine, dried (MgSO₄),
filtered and the filtrate concentrated to give a brown solid which was resuspended in
dioxane (15 mL) and triethylamine (3 mL) and heated to 140 °C in a sealed tube for 3
15 h, then cooled to rt. The reaction mixture was poured into aq. NH₄Cl and extracted
with EtOAc. The organic phases were combined, washed with brine, dried (MgSO₄),
filtered and the filtrate concentrated to give the title compound (1.66 g, 57 %) as a
tan solid. MS (ES+) m/e 444 [M+H]⁺.

20 Step 6. *N*-(3-([1-{4-[(2-Aminoethyl)oxy]phenyl}-2-(4-amino-furazan-3-yl)-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)acetamide

Triphenylphosphine (260 mg, 1.0 mmol) was added to a solution of the
product from Step 5 (220 mg, 0.5 mmol) and N-BOC-ethanolamine (161 mg, 1.0
mmol) in dioxane (4 mL) followed by addition of di-isopropylazodicarboxylate (197
25 uL, 1.0 mmol) and the resulting solution was allowed to stir at rt overnight. The
reaction mixture was poured into water and extracted with EtOAc. The organic
phases were combined, washed with brine, dried (MgSO₄), filtered and the filtrate
concentrated. The crude material was dissolved in dichloromethane (2 mL) and
treated with TFA (1 mL) for 30 min, then concentrated and the residue was purified
30 by reverse phase HPLC to give the title compound (38 mg, 16 %). MS (ES+) m/e
487 [M+H]⁺.

Example 3

4-{6-[(3-Aminophenyl)oxy]-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-furazan-3-amine

**Step 1. 2-Chloro-*N*-ethyl-5-nitro-4-pyridinamine**

The title compound was prepared by the method of Example 1, Step 4 starting from the product of Example 1, Step 3 and ethylamine. MS (ES+) *m/e* 202 [M+H]⁺.

Step 2. 1,1-Dimethylethyl (3-{[4-(ethylamino)-5-nitro-2-pyridinyl]oxy} phenyl)carbamate

The product of Step 1 (1.0 g, 5 mmol) in DMF (23 mL) was treated with 1,1-dimethylethyl (3-hydroxyphenyl) carbamate (1.3 g, 6 mmol) and potassium carbonate (6.9 g, 50 mmol). The resulting mixture was heated to 80 °C for 3 h., then partitioned between ethyl acetate and saturated aqueous ammonium chloride solution. The organic phase was washed with water and brine, then concentrated *in vacuo*. The residue was purified by column chromatography eluting with 20% ethyl acetate in hexane to afford the title compound (1.26 g, 68 %). MS (ES+) *m/e* 375 [M+H]⁺.

Step 3. 1,1-Dimethylethyl (3-{[5-amino-4-(ethylamino)-2-pyridinyl]oxy} phenyl)carbamate

The product from Step 2 (1.26 g, 3.3 mmol) in ethanol (20 mL) was hydrogenated for 3 hours in the presence of 10% palladium on carbon under H₂ (50 psi). After filtration of the catalyst through Kieselguhr, the filtrate was concentrated *in vacuo* to afford the title compound (0.81 g, 70 %). MS (ES+) *m/e* 345 [M+H]⁺.


**Step 4. 4-{6-[(3-Aminophenyl)oxy]-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl}-
furazan-3-amine**

The product from Step 3 (0.81 g, 2.3 mmol) and ethyl cyanoacetate (0.52 g, 4.6 mmol) were heated together at 195 °C for 25 minutes. After cooling the mixture to rt, the residue was dissolved in methanol (0.8 mL) and 5N hydrochloric acid (3 mL). The resulting mixture was treated portionwise with sodium nitrite (0.32 g, 4.6 mmol) and stirred at room temperature for 90 minutes. The pH of the mixture was adjusted to 11 by addition of 50% sodium hydroxide solution and a 50% solution of hydroxylamine in water (1.6 mL) was added. The mixture was heated at 110 °C for 16 h and the reaction allowed to cool to rt. The mixture was partitioned between ethyl acetate and water, then the organic phase was washed with brine and evaporated *in vacuo*. The residue was purified by HPLC to afford the title compound (0.12 g, 15 %). MS (ES+) *m/e* 338 [M+H]⁺.

15

Example 4


***N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-4-(methoxy)benzamide**



To a 0 °C solution of 0.10 g of the product of Example 3 (0.30 mmols) in DMF (1.0 mL) was added 0.041 mL of triethylamine (0.30 mmols) and 0.056 g of 4-methoxybenzoylchloride (0.33 mmols). The reaction mixture was allowed to warm to rt and stirred for 23 h. The reaction mixture was diluted with 1 mL of water and 5 mL of EtOAc. The layers were separated, and the aqueous layer was extracted with EtOAc. The combined organics were washed with water and concentrated to a partial volume. Methanol was added, and a solid precipitated from the solution. The precipitate was filtered off and dried and the crude product was purified by silica gel chromatography to provide the title compound as a white powder (0.029 g, 21 %). MS (ES+) *m/e* 473 [M+H]⁺.

Example 5


***N'*-(3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-*N,N*-dimethylsulfamide**



- 5 The title compound was prepared using *N,N*-dimethylsulfonyl chloride and the product from Example 3 via the same general procedure for example 4. MS (ES⁺) *m/e* 445 [M+H]⁺.

Example 6


***N*-(3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-3-pyridinecarboxamide**



- 15 To a room temperature suspension of 0.036 g of nicotinic acid (0.30 mmols) and 0.061 g of EDCI (0.32 mmols) in dry DMF (2.0 mL) was added 0.043 g of HOBt (0.32 mmols). After stirring for 10 min., 0.10 g of the product of Example 3 (0.3 mmols) was added to the reaction mixture. After stirring for 1 h, the reaction was treated with an additional 0.061 g of EDCI (0.32 mmols). The mixture was allowed to stir for 27 h at rt. The reaction mixture was diluted with 2 mL of water and 10 mL of EtOAc. The layers were separated, and the organic layer was washed with water. The organics were dried over MgSO₄, filtered, and concentrated. The yellow residue was washed with methanol to yield an off-white solid (73 mg, 57 %). MS (ES⁺) *m/e* 444 [M+H]⁺.

Example 7

***N*-(3-[2-(4-Amino-furazan-3-yl)-1-(1,2,3,4-tetrahydro-isoquinolin-7-yl)-1*H*-imidazo[4,5-*c*]pyridin-6-yloxy]-phenyl)-acetamide**



Step 1. 7-(2-Chloro-5-nitro-pyridin-4-ylamino)-3,4-dihydro-1 *H*-isoquinoline-2-carboxylic acid *tert*-butyl ester

5 To a solution of the 7-amino-3,4-dihydro-1 *H*-isoquinoline-2-carboxylic acid *tert*-butyl ester (5.2 g, 21.0 mmol) in ethanol (60 mL) and THF (15 mL) was added NaHCO₃ (5.3 g, 63.0 mmol) followed by the product of Example 1, Step 3 (4.05 g, 21.0 mmol), and the reaction mixture was stirred overnight rt. The reaction mixture was concentrated then taken up in EtOAc and H₂O extracted with EtOAc, the organic
10 layers were combined, dried over MgSO₄, filtered, and concentrated. The crude material was crystallized from EtOAc/hexane to give the title compound as a yellow solid. MS (ES+) *m/e* 406 [M+H]⁺.

Step 2. 7-[2-(3-Acetylaminophenoxy)-5-nitro-pyridin-4-ylamino]-3,4-dihydro-1 *H*-isoquinoline-2-carboxylic acid *tert*-butyl ester

A solution of 3-acetamidophenol (4.8 g, 32 mmol) in THF (200 mL) was cooled to 0 °C. To the solution was added NaH (60% in oil, 1.3g, 32 mol) and the mixture was warmed to rt and allowed to stir for 30 minutes. The product from Step 1 (~ 8.5 g, ~21 mmol) was added and the mixture was stirred at rt overnight then
20 DMF (10 mL) was added and the solution was heated to 60 °C overnight. The reaction mixture was concentrated *in-vacuo*, then taken up in EtOAc and H₂O and extracted with EtOAc. The organic layers were combined, dried over MgSO₄, filtered, and concentrated. The crude oil was purified chromatography to give the title compound (4.3 g, 39 %). MS (ES+) *m/e* 521 [M+H]⁺.

25

Step 3. 7-[2-(3-Acetylaminophenoxy)-5-amino-pyridin-4-ylamino]-3,4-dihydro-1 *H*-isoquinoline-2-carboxylic acid *tert*-butyl ester

The product from Step 2 (2.7 g, 5.2 mmol) was dissolved in MeOH (20 mL), Pd/C (5% on C, 100 mg) was added the mixture was hydrogenated with a balloon of

hydrogen for 2 days, then filtered through celite. The filtrate was concentrated to give the title compound which was taken on without purification. MS (ES+) m/e 491 [M+H]⁺.

5 **Step 4. 7-[6-(3-Acetylamino-phenoxy)-2-cyanomethyl-imidazo[4,5-c]pyridin-1-yl]-3,4-dihydro-1 H-isoquinoline-2-carboxylic acid *tert*-butyl ester**

The product from Step 3 (2.54 g crude) and cyanoacetic acid (0.88 g, 10.4 mmol) were dissolved in DMF (10 mL) and Et₃N (3.6 mL) was added. To the solution was added EDC (2.2g, 11.4mmol), and the mixture was allowed to stir at rt
10 for 2 days. The reaction mixture was poured into water and extracted with ethyl acetate. The separated organic layer was dried over MgSO₄, filtered, and concentrated to give a dark oil. The oil was dissolved in AcOH (5 mL) and the solution was heated at 100 °C for 4 hours then cooled and concentrated *in-vacuo* to give the title compound as a dark foam that was taken on without further purification.
15 MS (ES+) m/e 540 [M+H]⁺.


Step 5. N-{3-[2-(4-Amino-furazan-3-yl)-1-(1,2,3,4-tetrahydro-isoquinolin-7-yl)-1 H-imidazo[4,5-c]pyridin-6-yloxy]-phenyl}-acetamide

The product from Step 4 (0.250 g, 0.46 mmol) was dissolved in MeOH (5
20 mL) and 2N HCl (3 mL). To the solution was added NaNO₂ (0.065 g, 0.92 mmol), and the mixture was allowed to stir at rt for 30 min. The reaction mixture was concentrated, then dissolved in THF (3 mL). Triethylamine (0.25 mL), and NH₂OH (50% aqueous solution, 0.07 mL) were added and the mixture was heated in a sealed tube to 90 °C for 1 hour. The reaction mixture was then cooled, poured into
25 EtOAc and washed with H₂O. The organic layer was dried over MgSO₄, filtered, then concentrated *in-vacuo* to give a dark oil. The oil was dissolved in dioxane (3 mL) and Et₃N (0.5 mL) and the reaction mixture was heated in a sealed tube to 150 °C for 1 hour. The mixture was then cooled, and concentrated *in-vacuo*. The crude oil was dissolved in dichloromethane (2 mL) and to the solution was added 4N HCl
30 in dioxane and the resulting solution was allowed to stir at rt for 30 min. The mixture was then concentrated *in-vacuo*, and the oil was dissolved in a minimal

amount of MeOH then poured into Et₂O to afford the title compound as a tan solid (40 mg, 18 %). MS (ES+) m/e 484 [M+H]⁺.

Example 8

5 **3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}-*N*-[2-(4-morpholinyl)ethyl]benzamide**



Step 1. 2-Hydroxy-4-methoxy-5-nitropyridine

THF (100 mL) was cooled to -78 °C and anhydrous NH₃ (~200 mL) was
10 condensed into the THF. Potassium *t*-butoxide (45.5 g, 405 mmol) was added and the mixture was allowed to warm to ~ -35 °C. 4-Methoxy-3-nitropyridine (25.0 g, 162 mmol) was cooled to 0 °C in THF (200 mL) and a solution of *t*-BuOOH (5 M in decane, 34 mL, 170 mmol) was added over 10 min. This solution was then added dropwise to the KO*t*-Bu solution over 1 h, then stirred for 2 h at -35 °C and then
15 carefully quenched with ~50 mL of sat. NH₄Cl solution. The mixture was allowed to vent and warm to rt overnight, then the organics were concentrated and the residue made acidic with NH₄Cl solution and filtered. The solid was washed with cold H₂O and dried to give the title compound as a tan solid (14.0 g, 51%).

20 Step 2. 2,4-Dibromo-5-nitropyridine

Phosphorous oxybromide (5.73 g, 20 mmol) was added to a suspension of the product from Step 1 (1.70 g, 10 mmol) in acetonitrile (20 mL) at rt then heated to reflux for 3 h. The reaction mixture was cooled and carefully poured onto ice and sat. aq. K₂CO₃ then extracted with EtOAc. The organic extracts were combined,
25 washed with water and brine, dried (MgSO₄), filtered and concentrated to give the title compound (2.1 g, 75 %) as a dark solid. MS (ES+) m/e 279, 281, 285 [M+H]⁺.

Step 3. 2-Bromo-5-nitro-N-phenyl-4-pyridinamine

The product from Step 2 (7.55 g, 26.8 mmol) in THF (80 mL) and triethylamine (3.7 mL, 26.8 mmol) was treated with aniline (2.6 g, 27.9 mmol) and allowed to stir at rt until the reaction was judged complete by TLC. The solvent was removed *in vacuo* and the residue dissolved in ethyl acetate, washed (3x) with water and brine, dried over Na₂SO₄ and concentrated *in vacuo* to afford the title compound (7.65g, 97%). MS (ES+) m/e 294/296 [M+H]⁺.

Step 4. 6-Bromo-N⁴-phenyl-3,4-pyridinediamine

The product from Step 3 (7.42 g, 25.2 mmol) in acetic acid (80 mL) was treated with iron powder (5.65 g, 100.95 mmol) portionwise over 1 h while the temperature was maintained between 70-80 °C. The hot reaction mixture was quickly filtered through a pad of celite and washed with methanol. The combined filtrates concentrated to give a dark red residue was treated with NaHCO₃ and extracted with ethyl acetate. The organic layers were washed brine, dried over Na₂SO₄ and concentrated to afford the title compound (6.1 g, 95 %). MS (ES+) m/e 264/266 [M+H]⁺.

Step 5. (6-Bromo-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)acetonitrile

The product from Step 4 (2.1 g, 7.95 mmol) and ethyl cyanoacetate (3.6 g, 31 mmol) were heated together at 195°C in a sealed tube for 54 minutes. After cooling to room temperature, the product crystallized and the crystals were collected and washed with ethanol to give the title compound (0.87g, 35%). MS (ES+) m/e 313/315 [M+H]⁺.

Step 6. (6-Bromo-1-phenyl-1H-imidazo[4,5-c]pyridin-2-yl)(hydroxyimino)acetonitrile

The product from Step 5 (2.5 g, 7.99 mmol) in methanol (40 mL) and 2 N hydrochloric acid (16 mL) was treated portionwise with NaNO₂ (1.10 g, 16 mmol) and allowed to stir at rt for 1h. The resulting tan precipitate was filtered and washed

with methanol to give the title compound (2.7 g, 99 %). MS (ES+) m/e 342/344 [M+H]⁺.

Step 7. 4-(6-Bromo-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine

5 The product from Step 6 (2.7 g, 7.93 mmol) in THF (5 mL) and triethylamine (1.1 mL, 7.93mmol) was treated with a 50% solution of hydroxylamine in water (0.24 mL, 7.93 mmol). The mixture was heated at 120 °C in a sealed tube for 10 h and the reaction allowed to cool to room temperature. The resulting precipitate was filtered and dried in vacuo to afford the title compound (1.7g, 60%). MS (ES+) m/e
10 357/359 [M+H]⁺.

Step 8. Methyl 3-{{2-(4-amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}benzoate

15 A heterogeneous mixture of the product from Step 7 (0.75 g, 2.1 mmol), methyl 3-hydroxybenzoate (1.5 equiv), 1,10-phenanthroline (1.5 equiv), copper(I) iodide (0.42 g, 2.2 mmol) and cesium carbonate (1.44 g, 3.78 mmol) in toluene (30 mL) and ethyl acetate (1.5 mL) was heated in a sealed tube at 125 °C for 2 days. The reaction mixture was cooled to rt triturated with ethyl acetate. The resulting crude solid was crystallized from ethanol to afford the title compound (0.30 g, 33 %). MS
20 (ES+) m/e 429 [M+H]⁺.

Step 9. 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}benzoic acid


25 The product from Step 8 (0.22 g, 0.514 mmol) in THF (10 mL) was treated with a solution of 1N lithium hydroxide in water (1.5 mL) and heated to 65 °C for 10h. The reaction mixture was cooled and concentrated and the residue was partitioned between water and ethyl acetate. The aqueous phase was extracted with ethyl acetate and the organic layers were combined, washed with brine and dried over Na₂SO₄ and concentrated to give the title compound (0.20 g, 94 %). MS (ES+) m/e
30 415 [M+H]⁺.

Step 10. 3-{[2-(4-amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}-*N*-[2-(4-morpholinyl)ethyl]benzamide

The product from Step 9 (0.020 g, 0.048 mmol) in dichloromethane (2 mL) and *N,N*-diisopropylethylamine (0.02 mL, 0.11 mmol) was treated with *N*-(2-aminoethyl)morpholine and the PyBoP reagent (2 equiv) and stirred at rt for 2 h. The reaction mixture was concentrated and the residue was purified by reverse phase HPLC to give the compound (0.008 g, 31 %). MS (ES⁺) *m/e* 527 [M+H]⁺.

Example 9

10 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenol



Step 1. 3-{[(*t*-Butyl)-(dimethyl)silyl]oxy}phenol

1,3-Benzenediol (5 g, 45 mmol) in dichloromethane (150 mL) was treated with chloro(*t*-butyl)dimethylsilane (7.5 g, 50 mmol) and triethylamine (5 g, 50 mmol). The resulting mixture was stirred at rt for 16 h then concentrated *in vacuo* and the residue was partitioned between ethyl acetate and water. The organic phase was washed with 6N NaOH, then concentrated *in vacuo*. The residue was purified by column chromatography eluting with 20% ethyl acetate in hexane to afford the title compound (4.3 g, 42 %). MS (ES⁺) *m/e* 225 [M+H]⁺.

Step 2. 4-(6-Bromo-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine

The title compound was prepared from the product of Example 8, Step 2 and ethylamine by the general method of Example 8, Steps 3-6, followed by the general method of Example 2, Steps 4-5. MS (ES⁺) *m/e* 309, 311 [M+H]⁺.

Step 3. 3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenol


The product from Step 1 (46 mg, 0.20 mmol) in toluene (10 mL) was treated with the product from Step 2 (42 mg, 0.14 mmol), cuprous iodide (26 mg, 0.14

mmol), 1,10-phenanthroline (43 mg, 0.24 mmol), and cesium carbonate (88 mg, 0.27 mmol). The resulting mixture was heated to 120 °C for 48 hours in a sealed tube. After concentration the residue was purified by reverse phase HPLC to give the title compound (3.3 mg, 7 %). MS (ES+) m/e 339 [M+H]⁺.

5

Example 10


2-(4-Amino-furazan-3-yl)-1-ethyl-N-(phenylmethyl)-1H-imidazo[4,5-c]pyridin-6-amine



10 Under Ar, a suspension of the product from Example 9, Step 2 (18.9 mg, 61.1 μmol) in DMF (1 mL) was treated with benzylamine (12 μl, 110 μmol), copper iodide (2.3 mg, 12.2 μmol), phenyl 2-hydroxybenzoate (6.6 mg, 30.6 μmol), and potassium carbonate (16.9 mg, 122.2 μmol). This mixture was then heated to 170 °C by microwave for 40 min. After cooling to rt, the reaction mixture was diluted with
15 ethyl acetate and washed with water and brine. The organic layer was dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by reverse phase HPLC to give the title compound (2.6 mg, 10 %). MS (ES+) m/e 336 [M+H]⁺.

Example 11

3-[[2-(4-Amino-furazan-3-yl)-1-ethyl-1H-imidazo[4,5-c]pyridin-6-yl]thio]phenol




Under Ar, a suspension of the product from Example 9, Step 2 (15 mg, 48.5 μmol) in 1,4-dioxane (0.5 mL) and toluene (2.0 mL) was treated with tris(dibenzylidene-acetone)dipalladium (4.6 mg, 5 μmol), racemic-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (6.3 mg, 10 μmol), 3-[[[(1,1-dimethylethyl)(dimethyl)silyl]oxy]benzenethiol (14 ml, 58.2 μmol), and sodium *tert*-butoxide (6.6 mg, 67.9 μmol). This mixture was then heated to 175 °C by

25

microwave for 45 min. After cooling to rt, the reaction mixture was concentrated, redissolved in THF (3 mL) and treated with TBAF (0.5 mL, 1.0 M in THF) for 1 h. The reaction mixture was diluted with ethyl acetate (30 ml), washed with brine and the organic layer was dried over Na₂SO₄, filtered and concentrated *in vacuo*. The residue was purified by reverse phase HPLC to afford the title compound (4.4 mg, 16 %). MS (ES+) m/e 355 [M+H]⁺.

Example 12

***N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}phenyl)ethanethioamide**



10

Step 1. *N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}phenyl)acetamide

Under Ar, a suspension of the product from Example 9, Step 2 (50 mg, 162 μmol) in DME (1.4 mL) and toluene (2.8 mL) was treated with tris(dibenzylideneacetone)dipalladium (15 mg, 16 μmol), racemic-2,2'-bis(diphenylphosphino)-1,1'-binaphthyl (20 mg, 32 μmol), *N*-(3-mercaptophenyl)acetamide (32.6 mg, 195 μmol), and sodium *tert*-butoxide (22 mg, 227 μmol). This mixture was then heated to 175 °C by microwave for 15 min. After cooling to rt, the reaction mixture was diluted with ethyl acetate (30 ml), filtered through a celite pad and the filtrate was concentrated *in vacuo*. The residue was purified by reverse phase HPLC to give the title compound (17 mg, 26 %). MS (ES+) m/e 396 [M+H]⁺.

20


Step 2. *N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]thio}phenyl)ethanethioamide

The product from Step 1 (15 mg, 37.9 μmol) in THF (3 mL) was treated with Lawesson's reagent (20 mg, 49.4 μmol) at 120 °C by microwave for 30 min. The reaction mixture was concentrated *in vacuo* and the residue was purified by reverse phase HPLC to give the title compound (4.2 mg, 21 %). MS (ES+) m/e 412 [M+H]⁺.

25

Example 13


1-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)ethanone



- 5 Under nitrogen, a suspension of the product from Example 9, Step 2 (42.7 mg, 138 μ mol) in toluene (10 mL) was treated with copper iodide (26.3 mg, 138 μ mol), 1,10-phenanthroline (45 mg, 245 μ mol), 1-(3-hydroxyphenyl)ethanone (28.2 mg, 207 μ mol), and cesium carbonate (90 mg, 276 μ mol). This mixture was then heated to reflux for 36 h. After cooling to rt, the reaction mixture was diluted with
- 10 ethyl acetate (50 mL), filtered through a celite pad and then the filtrate was concentrated *in vacuo*. The residue was purified by reverse phase HPLC to give the title compound (28.1 mg, 43 %). MS (ES+) m/e 365 $[M+H]^+$.

Example 14

- 15 **4-{2-(4-amino-furazan-3-yl)-6-[(3-aminophenyl)oxy]-1*H*-imidazo[4,5-*c*]pyridin-1-yl}phenyl 2-methylpropanoate**



20

Step 1. 2-Chloro-5-nitro-*N*-{4-[(phenylmethyl)oxy]phenyl}-4-pyridinamine

- The product of Example 1, Step 3 (15.2 g, 78.7 mmol), 4-benzyloxyaniline·HCl (15.6 g, 78.7 mmol) and Et₃N (27 mL, 196.9 mmol) were combined in DMF (125 mL) and heated to 60 °C for 1h. The reaction mixture was
- 25 cooled and H₂O (200 mL) was added dropwise over 1h. The resulting yellow/orange

precipitate was filtered and washed with Et₂O to provide the title compound as a yellow powder (25.8 g, 92%). MS (ES+) m/e 356 [M+H]⁺.

Step 2. 1,1-Dimethylethyl (3-{{5-nitro-4-{{4-{{(phenylmethyl)oxy}}phenyl}}amino}-2-pyridinyl}oxy}phenyl)carbamate

A solution of 1,1-Dimethylethyl (3-hydroxyphenyl)carbamate (7.05 g, 33.7 mmol) in THF (20 mL) was added dropwise to a suspension of NaH (60% dispersion in oil, 1.34 g, 33.7 mmol) in THF (50 mL). The product of Step 1 (12.0 g, 33.7 mmol) in DMF (100 mL) was then added and the mixture was heated to 60 °C overnight. The reaction mixture was then cooled, poured into H₂O and extracted with EtOAc. The combined extracts were washed with brine, dried (MgSO₄), filtered and the filtrates were concentrated to give the title compound as a yellow solid (16.4 g, 92%) which was used without purification. MS (ES+) m/e 529 [M+H]⁺.

Step 3. 1,1-Dimethylethyl [3-{{5-amino-4-{{(4-hydroxyphenyl)amino}}-2-pyridinyl}oxy}phenyl]carbamate

The product from Step 2 (16.4 g, 31.0 mmol) was hydrogenated with a balloon of H₂ in the presence of 5% Pd/C (2 g) in MeOH (100 mL) over the weekend. The reaction mixture was then filtered through Celite and concentrated to give the title compound (13g, quant.) which was used without purification. MS (ES+) m/e 409 [M+H]⁺.

Step 4. 4-{{2-{{(4-amino-furazan-3-yl)-6-{{(3-aminophenyl)oxy}}-1H-imidazo[4,5-c]pyridin-1-yl}}phenol

The title compound was prepared from the product of Step 3 by the general procedures of Example 1, Steps 7-8 followed by removal of the BOC group by treatment with trifluoroacetic acid to give the title compound. MS (ES+) m/e 402 [M+H]⁺.

Step 5. 4-{{2-{{(4-Amino-furazan-3-yl)-6-{{(3-aminophenyl)oxy}}-1H-imidazo[4,5-c]pyridin-1-yl}}phenyl 2-methylpropanoate


A solution of the product of Step 4 (80 mg, 0.20 mmol) and 2-methylpropanoic acid (18.4 mg, 0.21 mmol) in 2 ml DMF was treated with 1-hydroxybenzotriazole hydrate (HOBT)(29.7mg, 0.22 mmol). The resulting mixture was stirred for 10 minutes at room temperature before being treated with

5 triethylamine (22 mg, 0.22mmol) and 1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide hydrochloride (EDC) (42 mg, 0.22 mmol). The reaction was kept at room temperature overnight. Purification of the crude mixture by reverse phase (CH₃CN 30% - 80% in H₂O with 0.1%TFA) afforded 20 mg (31%) oil as title compound. ¹H NMR (400 MHz, DMSO-D₆) δ ppm 8.89 (s, 1H), 7.68 (d, 2H, 8.8Hz),

10 7.38 (d, 2H, 8.8Hz), 7.32 (t, 1H, 8.0Hz), 6.85 (d, 1H, 7.6Hz), 6.79-6.91 (m, 3H), 5.5-6.8 (M,6H), 2.88 (m, 1H), 1.28 (d, 6H, 6.8Hz). MS (ES+) m/e 372.2 [M+H]⁺.

Example 15

Methyl 3-{{2-(4-amino-furazan-3-yl)-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}benzoate



Step 1. 2-bromo-5-nitro-4-pyridinamine

Under nitrogen, to a solution of 2,4-dibromo-5-nitropyridine in THF (150 mL), was added ammonia (2.0M in MeOH), followed with triethylamine (5mL).

20 This mixture was then stirred at rt for 50 h. The reaction mixture was concentrated, taken up in EtOAC, filtered through a silica gel pad, and then concentrated *in vacuo* to afford the title compound (3.67 g, 95%). MS (ES+) m/e 218 [M+H]⁺.

Step 2. Methyl 3-[(4-amino-5-nitro-2-pyridinyl)oxy]benzoate

25 Under nitrogen, to a solution of 2-bromo-5-nitro-4-pyridinamine (3.67g, 16.8 mmol) and methyl 3-hydroxybenzoate (2.82 g, 18.5 mmol) in DMF (100 mL), was added NaH (810 mg, 60% suspension, 20.2 mmol). 5 min later, the reaction mixture was heated to 65 °C. The reaction mixture was concentrated, taken up in EtOAC, washed with NaOH solution (1.0N), saturated NH₄Cl solution and brine, dried over

Na₂SO₄, filtered and concentrated to afford the title compound, which was used directly to next step without further purification. MS (ES+) m/e 290 [M+H]⁺.

Step 3. Methyl 3-[(4,5-diamino-2-pyridinyl)oxy]benzoate

5 To a solution of the product of Step 2 in MeOH (180 mL) and EtOAc (50 mL), was added 10% palladium on carbon (280mg). This mixture was then stirred under hydrogen atmosphere for 36 h. The reaction mixture was filtered and then concentrated to afford the title compound, which was used directly to next step without further purification. MS (ES+) m/e 260 [M+H]⁺.

10

Step 4. Methyl 3-({4-amino-5-[(cyanoacetyl)amino]-2-pyridinyl}oxy)benzoate

To a solution of the product of Step 3 in THF (150 mL), was added cyanoacetic acid (870 mg, 10.2 mmol), EDC (4.32g, 22.5 mmol) and triethylamine (8 ml, 51 mmol). This mixture was then stirred at rt for overnight. The reaction
15 mixture was concentrated, taken up in EtOAc (300mL), washed with saturated NaHCO₃ solution and brine, dried over Na₂SO₄, filtered and concentrated. The residue was dissolved in AcOH (100ml), and then heated to 115 °C for 24 h. The reaction mixture was concentrated to afford the title compound, which was used directly to next step without further purification. MS (ES+) m/e 309 [M+H]⁺.

20


Step 5. Methyl 3-{[2-(4-amino-furazan-3-yl)-1H-imidazo[4,5-c]pyridin-6-yl]oxy}benzoate

To a solution of the product of Step 4 in MeOH (200 mL), was added NaNO₂ (1.45 g, 20.4 mmol), followed by 2N HCl (50 ml, 100mmol). After 2 h, this mixture
25 was concentrated and filtered. The residue was taken up in THF (50mL), NH₂OH (50% aq. soln. 5 mL) and triethylamine (6 mL) were added and the mixture was then heated to 90 °C for 80 min in a sealed tube. The reaction mixture was diluted with EtOAc (100 mL), washed with saturated NH₄Cl solution and brine, dried over Na₂SO₄, filtered and concentrated. The residue was then purified with flash
30 chromatography (hexanes/ethyl acetate 3:1), to afford the title compound as a pale yellow solid (215 mg, 7% for 6 steps). ¹H NMR (400 MHz, DMSO) δ ppm 8.74 (s,

1H), 7.79 (d, 1H, 8.0Hz), 7.51-7.56 (m, 3H), 7.44 (dd, 1H, 8.0Hz, 2.0Hz), 7.22 (bs, 1H), 6.81 (s, 1H), 3.85 (s, 3H). MS (ES+) m/e 353 [M+H]⁺.

Example 16

5 1-(3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-4-(4-morpholinyl)-1-butanol



Step 1. 4-chloro-*N*-methyl-*N*-(methoxy)butanamide

10 To a solution of 4-chlorobutanoyl chloride (5.64 g, 40.0 mmol) and a *N*,*O*-dimethylhydroxylamine hydrochloride (3.91 g, 40.0 mmol) in CH₂Cl₂ (80 mL) at 0 °C, was added pyridine (7.2 mL, 88.0 mmol) in CH₂Cl₂ (30 mL). This mixture was kept stirring at 0 °C for 1h, then warmed to rt. The reaction mixture then diluted with Et₂O (200 mL), washed with saturated 1N HCl (2X), saturated NaHCO₃ solution and
15 brine, dried over Na₂SO₄, filtered and concentrated to afford the title compound as a colorless oil (6.28 g, 95%). MS (ES+) m/e 166 [M+H]⁺.

Step 2. *N*-methyl-*N*-(methoxy)-4-(4-morpholinyl)butanamide

To a solution of the product from Step 1 (3.01 g, 18.1 mmol) in MeCN (40 mL), was added K₂CO₃ (10 g, 72.4 mmol) and morpholine (1.58 mL, 18.1 mmol).
20 This mixture was then heated to 105 °C in a sealed tube for overnight. The reaction mixture then diluted with MeCN (50 mL), then filtered and concentrated. Residue was taken up in Et₂O (100 mL), washed with brine, dried over Na₂SO₄, filtered and concentrated to afford the title compound as a colorless oil (1.73 g, 44%), which was
25 used directly to next step without further purification. MS (ES+) m/e 217 [M+H]⁺.

Step 3. 4-(4-morpholinyl)-1-{3-[(phenylmethyl)oxy]phenyl}-1-butanone

Under argon, to a solution of 1-bromo-3-[(phenylmethyl)oxy]benzene (2.04 g, 7.76 mmol) in THF (30 mL) at -78 °C, was added dropwise *n*-BuLi (5.1 mL, 1.6 M in Hexanes), 20 min after the addition, this solution was added to a solution the product from Step 3 (1.68 g, 7.76 mmol) in THF (30 mL) under argon at -78 °C. 15 min later, the reaction mixture was slowly warmed to 0 °C. The reaction mixture was poured into a mixture of EtOAC and NH₄Cl, then extracted with EtOAC (2X), organic layers were combined, washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was then purified with flash chromatography (hexanes/ethyl acetate 1:4), to afford the title compound as a colorless oil (932 mg, 35%). MS (ES+) *m/e* 340 [M+H]⁺.

Step 4. 1-(3-hydroxyphenyl)-4-(4-morpholinyl)-1-butanone

To a solution of the product of Step 3 (352 mg, 1.04 mmol) in EtOH (15 mL), was added 10% palladium on carbon (50mg), followed with 1-methyl-1,4-cyclohexadiene (1.5 mL). This suspension was then heated to reflux for 45 min. The reaction mixture was filtered and concentrate to afford the title compound as a white solid (255 mg, 99%). MS (ES+) *m/e* 250 [M+H]⁺.

Step 5. 1-(3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-4-(4-morpholinyl)-1-butanone


Under argon, to a suspension of 4-(6-bromo-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine (prepared by the method of Example 8, Steps 3-7, substituting ethylamine for aniline in Step 3) (80 mg, 0.26mmol) in toluene (4mL) and DME (4 mL), was added the product of Step 4 (78 mg, 0.31mmol), CuI (50 mg, 0.26 mmol), 1,10-phenanthroline (94 mg, 0.52 mmol), and Cs₂CO₃ (170 mg, 0.52 mmol). This mixture was then heated to 170 °C by microwave for 15 min. The reaction mixture was added DMSO (1.5 mL), diluted with EtOAC/ MeOH, sonicated for 10 min, then filtered and concentrated. The residue was purified with reverse phase HPLC (10% MeCN/H₂O → 80% MeCN/H₂O, containing 0.1% TFA), to afford the title compound as a pale yellow solid (66 mg, 43%). MS (ES+) *m/e* 478 [M+H]⁺.

Step 6. 1-(3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-4-(4-morpholinyl)-1-butanol

To a solution of the product of Step 5 (66mg, 0.14 mmol) in wet THF, was added NaBH₄ (16 mg, 0.36 mmol). This mixture was stirred at rt for 1h. DMSO (2mL) was added and the reaction mixture was then concentrated. The residue was purified with reverse phase HPLC (10% MeCN/H₂O → 80% MeCN/H₂O, containing 0.1% TFA), to afford the title compound as a pale yellow solid (6.5 mg, 10%). ¹H NMR (400 MHz, DMSO) δ ppm 9.56 (bs, 1H), 8.76 (d, 1H, 0.8 Hz), 7.54 (s, 1H), 7.39 (t, 1H, 8.0Hz), 7.16 (d, 1H, 7.6Hz), 7.09 (d, 1H, 2.0Hz), 6.96-6.99 (m, 2H), 5.44 (bs, 1H), 4.68 (q, 2H, 7.2Hz), 4.60 (t, 1H, 7.0Hz), 3.97 (d, 2H, 11.2Hz), 3.62 (t, 2H, 12.0Hz), 3.38 (d, 2H, 10.0Hz), 2.99-3.13 (m, 4H), 1.58-1.75 (m, 4H), 1.41 (t, 3H, 7.2Hz). MS (ES+) m/e 480 [M+H]⁺.

Example 17

15 **4-[1-ethyl-6-({3-[(1*E*)-3-(4-methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]phenyl}oxy)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furazan-3-amine**



Step 1. 3-[(1*E*)-3-(4-methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]phenol


Under nitrogen, to a solution of (2*E*)-3-(3-hydroxyphenyl)-2-propenoic acid (330 mg, 2.0 mmol) in THF (20 mL), was added 1-methylpiperazine (400 mg, 4.0 mmol), HOBT (810 mg, 6.0 mmol), HBTU (760 mg, 2 mmol), followed with 4-methylmorpholine (670 μ L, 6.0 mmol). This mixture was then stirred at rt for overnight. The reaction mixture was concentrated and the residue was purified with reverse phase HPLC (5% MeCN/H₂O \rightarrow 60 % MeCN/H₂O) to afford the title compound as a white solid (397 mg, 81%). MS (ES⁺) *m/e* 247 [M+H]⁺.

Step 2. 4-[1-ethyl-6-({3-[(1*E*)-3-(4-methyl-1-piperazinyl)-3-oxo-1-propen-1-yl]phenyl}oxy)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furazan-3-amine

Under argon, to a suspension of 4-(6-bromo-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine (prepared by the method of Example 8, Steps 3-7, substituting ethylamine for aniline in Step 3) (80 mg, 0.26mmol) in toluene (4mL) and DME (4 mL), was added the product of Step 1 (100 mg, 0.41mmol), CuI (50 mg, 0.26 mmol), 1,10-phenanthroline (94 mg, 0.52 mmol), and Cs₂CO₃ (170 mg, 0.52 mmol). This mixture was then heated to 170 °C by microwave for 20 min. The reaction mixture was added DMSO (2.0 mL), diluted with EtOAc/ MeOH, sonicated for 10 min, then filtered and concentrated. Residue was purified with reverse phase HPLC (10% MeCN/H₂O → 80% MeCN/ H₂O, containing 0.1% TFA), to afford the title compound as a pale yellow solid (26.3 mg, 17%). ¹H NMR (400 MHz, MeOD) δ ppm 8.72(s, 1H), 7.65 (d, 1H, 15.6Hz), 7.45-7.52 (m, 3H), 7.28 (s, 1H), 7.21 (d, 1H, 15.6Hz), 7.16-7.18 (m, 1H), 4.72 (q, 2H, 7.2Hz), 3.60 (bs, 4H), 3.16 (bs, 4H), 2.97 (s, 3H), 1.47 (t, 3H, 7.2Hz). MS (ES+) m/e 475 [M+H]⁺.

Example 18

4-[1-ethyl-6-({3-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]phenyl}oxy)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furazan-3-amine



Step 1. 3-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]phenol


To a solution the product of Example 17, Step 1 (300 mg, 1.22 mmol) in EtOH (15 mL), was added 10% palladium on carbon (50mg), followed with 1-methyl-1,4-cyclohexadiene (1.5 mL). This suspension was then heated to reflux for 45 min. The reaction mixture was filtered and concentrated to afford the title compound, as a white solid (291 mg, 96%). MS (ES+) m/e 249 [M+H]⁺.

Step 2. 4-[1-ethyl-6-({3-[3-(4-methyl-1-piperazinyl)-3-oxopropyl]phenyl}oxy)-1*H*-imidazo[4,5-*c*]pyridin-2-yl]-furazan-3-amine

Under argon, to a suspension of 4-(6-bromo-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine (prepared by the method of Example 8, Steps 3-7, substituting ethylamine for aniline in Step 3) (100 mg, 0.32 mmol) in toluene (5 mL) and DME (5 mL), was added the product of Step 1 (128 mg, 0.52 mmol), CuI (62 mg, 0.32 mmol), 1,10-phenanthroline (116 mg, 0.65 mmol), and Cs₂CO₃ (210 mg, 0.65 mmol). This mixture was then heated to 170 °C by microwave for 40 min. To the reaction mixture was added DMSO (2.0 mL), diluted with EtOAc/ MeOH, sonicated for 10 min, then filtered and concentrated. Residue was purified with reverse phase HPLC (10% MeCN/H₂O → 80% MeCN/H₂O, containing 0.1% TFA), to afford the title compound as a pale yellow solid (12.0 mg, 8 %). ¹H NMR (400 MHz, MeOD) δ ppm 8.71 (d, 1H, 0.8Hz), 7.35 (t, 1H, 8.0Hz), 7.19 (d, 1H, 0.8Hz), 7.10 (d, 1H, 7.6Hz), 6.94-7.10 (m, 2H), 4.72 (q, 2H, 7.2Hz), 3.42-3.61 (m, 4H), 2.96 (t, 2H, 7.6Hz), 2.74 (t, 2H, 7.6Hz), 2.40-2.48 (m, 4H), 2.35 (s, 3H), 1.46 (t, 3H, 7.2Hz). MS (ES⁺) *m/e* 477 [M+H]⁺.

Example 19

1-(3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-2-methyl-4-(4-morpholinyl)-1-butanone



Step 1. 2-methyl-4-(4-morpholinyl)-1-{3-[(phenylmethyl)oxy]phenyl}-1-butanone

To a solution of 4-(4-morpholinyl)-1-{3-[(phenylmethyl)oxy]phenyl}-1-butanone (88 mg, 0.26 mmol) in THF (3 mL), was added NaH (23 mg, 60% suspension, 0.57 mmol). This suspension was stirred at rt for 30 min, then MeI (25 µL, 0.39 mmol) was added. The reaction mixture was stirred at rt for 3 h, then

quenched with water. The reaction mixture was added EtOAC (100 ml), washed with brine, dried over Na₂SO₄, filtered and concentrated. The residue was then purified with flash chromatography (hexanes/ethyl acetate 1:2), to afford the title compound as a colorless oil (74 mg, 81%). MS (ES+) m/e 354 [M+H]⁺.

5

Step 2. 1-(3-hydroxyphenyl)-2-methyl-4-(4-morpholinyl)-1-butanone

To a solution of the product of Step 1 (119 mg, 0.34 mmol) in EtOH (10 mL), was added 10% palladium on carbon (50mg), followed with 1-methyl-1,4-cyclohexadiene (1 mL). This suspension was then heated to reflux for 15 min. The reaction mixture was filtered and concentrate to afford the title compound as a white solid (88 mg, 99%). MS (ES+) m/e 264 [M+H]⁺.

10

Step 3. 1-(3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-2-methyl-4-(4-morpholinyl)-1-butanone


15

Under argon, to a suspension of 4-(6-bromo-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine (prepared by the method of Example 8, Steps 3-7, substituting ethylamine for aniline in Step 3) (80 mg, 0.26 mmol) in toluene (4 mL) and DME (4 mL), was added the product of Step 2 (88 mg, 0.31 mmol), CuI (50 mg, 0.26 mmol), 1,10-phenanthroline (94 mg, 0.52 mmol), and Cs₂CO₃ (170 mg, 0.52 mmol). This mixture was then heated to 170 °C by microwave for 15 min. To the reaction mixture was added DMSO (2.0 mL), diluted with EtOAC/ MeOH, sonicated for 10 min, then filtered and concentrated. The residue was purified with reverse phase HPLC (10% MeCN/H₂O → 80% MeCN/H₂O, containing 0.1% TFA), to afford the title compound as a pale yellow solid (72.0 mg, 46%). ¹H NMR (400 MHz, DMSO) δ ppm 9.71 (bs, 1H), 8.77 (d, 1H, 0.8Hz), 7.84 (d, 1H, 8.0Hz), 7.69 (t, 1H, 2Hz), 7.59-7.64 (m, 2H), 7.45 (dd, 1H, 8Hz, 0.8Hz), 6.96 (s, 2H), 4.70 (q, 2H, 7.2Hz), 3.98 (d, 2H, 12.4Hz), 3.60-3.81 (m, 2H), 3.42-3.47 (m, 2H), 3.01-3.19 (m, 4H), 1.96-2.01 (m, 1H), 1.41 (t, 3H, 7.2Hz), 1.38 (d, 3H, 10.4Hz). MS (ES+) m/e 492 [M+H]⁺.

20

25

30

Example 20**1-(3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-4-(4-methyl-1-piperazinyl)-4-oxo-1-butanone**

5

Step 1. 4-(3-{[(1,1-dimethylethyl)(dimethyl)silyl]oxy}phenyl)-4-oxobutanoic acid

Under argon, to a solution of [(3-bromophenyl)oxy](1,1-dimethylethyl)-dimethylsilane (1.5 g, 5.22 mmol) in THF (60 mL) at -78 °C, was added dropwise *n*-BuLi (3.6 mL, 1.6 M in hexanes), 20 min after the addition, this solution was added
 10 to a solution of dihydro-2,5-furandione (630 mg, 6.26 mmol) in THF (10 mL) under argon at -78 °C. 15 min later, the reaction mixture was slowly warmed to rt overnight. The reaction mixture was diluted with EtOAc (50 mL), then extracted with NaOH (20 mL, 1.0 N). Aqueous layer was acidified with HCl (1.0 N) until pH = 2, then extracted with EtOAc (100 mL). The organic layer was washed with brine,
 15 dried over Na₂SO₄, filtered and concentrated to afford the title compound as a colorless crystal (546 mg, 54%). MS (ES+) *m/e* 195 [M+H]⁺.

Step 2. 1-(3-hydroxyphenyl)-4-(4-methyl-1-piperazinyl)-4-oxo-1-butanone


Under nitrogen, to a solution of the product of Step 1 (490 mg, 2.52 mmol) in
 20 DMF (10 mL), was added 1-methylpiperazine (505 mg, 5.04 mmol), HOBT (1.02 g, 7.6 mmol), HBTU (950 mg, 2.5 mmol), followed with 4-methylmorpholine (770 µL, 7.6 mmol). This mixture was then stirred at rt overnight. The reaction mixture was concentrated and the residue was purified with reverse phase HPLC (5% MeCN/H₂O → 50 % MeCN/H₂O), to afford the title compound as white solid (572 mg, 82%).
 25 MS (ES+) *m/e* 277 [M+H]⁺.

Step 3. 1-(3-{[2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-4-(4-methyl-1-piperazinyl)-4-oxo-1-butanone

Under argon, to a suspension of 4-(6-bromo-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine (prepared by the method of Example 8, Steps 3-7, substituting ethylamine for aniline in Step 3) (80 mg, 0.26 mmol) in toluene (4 mL) and DME (4 mL), was added the product of Step 2 (145 mg, 0.52 mmol), CuI (50 mg, 0.26 mmol), 1,10-phenanthroline (94 mg, 0.52 mmol), and Cs₂CO₃ (210 mg, 0.65 mmol). This mixture was then heated to 170 °C by microwave for 25 min. The reaction mixture was added DMSO (2.0 mL), diluted with EtOAc/ MeOH, sonicated for 10 min, then filtered and concentrated. The residue was purified with reverse phase HPLC (10% MeCN/H₂O → 80% MeCN/H₂O, containing 0.1% TFA), to afford the title compound as a pale yellow solid (7.3 mg, 5%). ¹H NMR (400 MHz, MeOD) δ ppm 8.75 (s, 1H), 7.91 (d, 1H, 7.6Hz), 7.73-7.75 (m, 1H), 7.59 (td, 1H, 8.0Hz, 2.0Hz), 7.45 (dt, 1H, 8Hz, 0.8Hz), 7.36 (s, 1H), 4.77 (q, 2H, 7.2Hz), 3.40-3.58 (m, 8H), 2.86-3.14 (m, 4H), 2.98 (s, 3H), 1.50 (t, 3H, 7.2Hz). MS (ES⁺) m/e 505 [M+H]⁺.

Example 21

3-{{2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl)methyl}-*N*-[2-(4-morpholinyl)ethyl]benzamide



Step 1. Methyl 3-{{2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl)methyl}benzoate

Under argon, to a suspension of Rieke Zinc (650 µl, 5 % suspension in THF), was added dropwise methyl 3-(bromomethyl)benzoate (118 mg, 0.50 mmol) in THF (5 mL). This mixture was heated briefly to reflux with a heat gun, then cooled to rt and stirred for 4 h. The above mixture was then filtered into a mixture of 4-(6-bromo-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-2-yl)-furazan-3-amine (prepared by the

method of Example 8, Steps 3-7, substituting ethylamine for aniline in Step 3) (110 mg, 0.36 mmol) and tetrakis(triphenylphosphine)palladium (15 mg, 13 mmol), then heated to 110 °C by microwave for 20 min. The reaction mixture was added DMSO (2.0 mL) and concentrated. Residue was purified with reverse phase HPLC (10% MeCN/H₂O → 80% MeCN/H₂O), to afford the title compound as a pale yellow solid (96.6 mg, 72%). MS (ES+) m/e 379 [M+H]⁺.

Step 2. 3-{{2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl)methyl}benzoic acid


To a solution of the product from Step 1 (85 mg, 0.22 mmol) in MeOH (12 ml) and water (4 ml), was added LiOH (40 mg, 0.95 mmol). This mixture was then heated to 80 °C for 2 h. Reaction mixture was concentrated, dissolved in 10 ml water, acidified with 1 N HCl to pH = 5, then filtered and washed with water to afford a pale yellow solid (67 mg, 82%). MS (ES+) m/e 365 [M+H]⁺.

Step 3. 3-{{2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl)methyl}-*N*-[2-(4-morpholinyl)ethyl]benzamide

Under nitrogen, to a solution of the product of Step 2 (31 mg, 85 μmol) in DMF (2 mL), was added [2-(4-morpholinyl)ethyl]amine (23 mg, 170 μmol), HOBt (35 mg, 0.26 mmol), HBTU (49 mg, 0.13 mmol), followed with 4-methylmorpholine (30 μL, 0.26 mmol). This mixture was then stirred at rt for overnight. The reaction mixture was concentrated, residue was purified with reverse phase HPLC (10% MeCN/H₂O → 80 % MeCN/H₂O, containing 0.1% TFA), to afford the title compound as a pale yellow solid (53 mg, 90%). ¹H NMR (400 MHz, DMSO) δ ppm 9.74 (t, 1H, 4.4 Hz), 9.28 (s, 1H), 8.73 (t, 1H, 5.2 Hz), 8.16 (s, 1H), 7.87 (s, 1H), 7.73 (d, 1H, 8.0Hz), 7.56 (d, 1H, 7.2Hz), 7.49 (d, 1H, 7.6Hz), 6.96 (s, 2H), 4.72 (q, 2H, 7.2Hz), 4.41 (s, 2H), 4.00 (d, 2H, 11.2Hz), 3.53-3.68 (m, 6H), 3.30 (bs, 2H), 3.14-3.17 (m, 2H), 1.42 (t, 3H, 7.2Hz). MS (ES+) m/e 477 [M+H]⁺.


Example 22

***N*-(3-{{2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}phenyl)-4-{{2-(4-morpholinyl)ethyl}oxy}benzamide**



***N*-(3-([2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-4-([2-(4-morpholinyl)ethyl]oxy}benzamide**

Under argon, to a suspension of the HCl salt of 4-([2-(4-morpholinyl)ethyl]oxy}benzoic acid (3.98 g, 13.8 mmol) in CH₂Cl₂ (100 ml) was added DMF (40 µl), followed with oxalylchloride (3.6 ml, 41.4 mmol). This mixture was then heated to reflux until a clear solution resulted. The reaction mixture was then concentrated, added CH₂Cl₂ (20 mL) and reconcentrated. A suspension of the above product in CH₂Cl₂ (100 mL), was added to a suspension of the product of Example 3 (3.96 g, 11.7 mmol) in pyridine (30 mL). This mixture was then heated to 70 °C, the CH₂Cl₂ was distilled off, then stirred for 1 h. CH₂Cl₂ (200 mL) was added to the cooled reaction mixture, stirred for 15 min and then filtered to provide a first crop of product (crop 1). The filtrate was concentrated in vacuo and the residue taken up in EtOAc, washed with water (4 X), brine, dried over Na₂SO₄, filtered and concentrated to provide Crop 2. Crops 1 and 2 were combined and recrystallized from MeOH to afford a off white solid (5.54 g, 83%). ¹H NMR (400 MHz, DMSO) δ ppm 11.35 (bs, 1H), 10.22 (s, 1H), 8.79 (d, 1H, 0.8 Hz), 7.99 (d, 2H, 8.8 Hz), 7.58-7.64(m, 3H), 7.37 (t, 1H, 8.0Hz), 7.12 (d, 2H, 8.8 Hz), 6.95 (s, 2H), 6.84-6.87 (m, 1H), 4.70 (q, 2H, 7.2Hz), 4.53 (bs, 2H), 3.81-3.98 (m, 4H), 3.49-3.58 (m, 4H), 3.18-3.36(m, 2H), 1.41 (t, 3H, 7.2Hz). MS (ES+) m/e 571 [M+H]⁺.

Example 23**3-{{2-(4-amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}-*N*-[2-(4-morpholinyl)ethyl]benzenesulfonamide****5 Step 1. 3-(Methoxy)-*N*-[2-(4-morpholinyl)ethyl]benzenesulfonamide**

2-Morpholinoethylamine (1.75 mL, 13.3 mmol) was added over 10 min to a solution of 3-(methoxy)benzenesulfonyl chloride (2.5 g, 12.1 mmol) in CH₂Cl₂ (10 mL) and pyridine (4 mL) and the resulting solution was stirred at rt for 1 h. The mixture was concentrated, dissolved in EtOAc and the organic phase was washed
 10 with H₂O and brine, dried (MgSO₄), filtered and the filtrate was concentrated to give an orange oil (3.3 g, 92%) which was used directly in the next step. MS (ES+) m/e 301 [M+H]⁺.

Step 2. 3-Hydroxy-*N*-[2-(4-morpholinyl)ethyl]benzenesulfonamide

15 A solution of boron tribromide (1M in CH₂Cl₂, 20 mL, 20 mmol) was added to a -78 °C solution of the product of Step 1 in CH₂Cl₂ (50 mL) and the resulting mixture was allowed to warm to 0 °C. After 2h at 0 °C the mixture was re-cooled to -78 °C and quenched with sat. aq. NaHCO₃ solution and allowed to warm to rt. The mixture was extracted with EtOAc, and the organic layers was washed with H₂O and
 20 brine, dried (MgSO₄), filtered and the filtrate was concentrated to give the title compound as a crude oil (1.9 g, 66%) which was used directly in the next step. MS (ES+) m/e 287 [M+H]⁺.

25 Step 3. *N*-[2-(4-Morpholinyl)ethyl]-3-{{5-nitro-4-(phenylamino)-2-pyridinyl}oxy}benzenesulfonamide

A solution of the product of Step 2 (1.9 g, 6.6 mmol) in DMF (10 mL) was added dropwise over 10 min to a suspension of NaH (60% dispersion in oil, 265 mg, 6.6 mmol) in DMF (10 mL). After the final addition, a solution of the product of Example 1, Step 4 (1.65 g, 6.6 mmol) in DMF (15 mL) was added and the reaction

mixture was heated to 60 °C overnight. The reaction mixture was cooled, poured into H₂O and extracted with EtOAc. The organic layers were combined, washed with H₂O and brine, dried (MgSO₄), filtered and the filtrate was concentrated. The crude product was purified by column chromatography (10%-100% EtOAc in hexane) to give the title compound as an orange oil (3.3 g, quant.). MS (ES+) m/e 500 [M+H]⁺.

Step 4. 3-{{[5-Amino-4-(phenylamino)-2-pyridinyl]oxy}-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide

The product of Step 3 (3.3 g, 6.6 mmol) was hydrogenated overnight with a balloon of hydrogen gas in MeOH (50 mL) in the presence of 5% Pd/C (300 mg). The reaction mixture was filtered through Celite and concentrated to give the title compound as a dark oil which was used directly in the next step (~3.1 g, quant.).

Step 5. 3-{{[2-(Cyanomethyl)-1-phenyl-1H-imidazo[4,5-c]pyridin-6-yl]oxy}-N-[2-(4-morpholinyl)ethyl]benzenesulfonamide

The product of Step 4 (3.1 g, 6.6 mmol), cyanoacetic acid (1.1 g, 13.2 mmol) and EDCI (2.5 g, 13.2 mmol) were combined in CH₂Cl₂ (25 mL). Triethylamine (3.7 mL, 26.4 mmol) was added and the resulting solution was allowed to stir overnight at rt. The reaction mixture was poured into H₂O and extracted with EtOAc. The organic layers were combined, washed with H₂O and brine, dried (MgSO₄), filtered and the filtrate was concentrated to give the crude amide which was used directly.

The crude amide from above was heated to 110 °C in glacial acetic acid (15 mL) for 5 h. The reaction mixture was then cooled and concentrated, the residue was made basic with aq. K₂CO₃ solution and the mixture was extracted with EtOAc. The organic layers were combined, washed with H₂O and brine, dried (MgSO₄), filtered and the filtrate was concentrated to give an oil which was purified by column chromatography (0%-5% MeOH in CH₂Cl₂) to give the title compound (2.4 g, 71% over two steps) as an off white foam. MS (ES+) m/e 519 [M+H]⁺.


Step 6. 3-{{2-(4-Amino-furazan-3-yl)-1-phenyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}-*N*-[2-(4-morpholinyl)ethyl]benzenesulfonamide

Sodium nitrite (100 mg, 1.4 mmol) was added to a solution of the product of Step 5 (500 mg, 0.96 mmol) in MeOH (5 mL) and 1M HCl (4 mL) and the resulting mixture was allowed to stir at rt for 30 min. The reaction mixture was poured into H₂O and extracted with EtOAc. The organic layers were combined, washed with H₂O and brine, dried (MgSO₄), filtered and the filtrate was concentrated to give a solid which was triturated with MeOH to give the desired oxime (271 mg, 52%) as a tan solid which was used directly in the next step. MS (ES+) *m/e* 549 [M+H]⁺.

A slurry of the oxime from above (270 mg, 0.5 mmol) in dioxane (5 mL) and Et₃N (2 mL) was treated with hydroxylamine (50% aq. soln., 30 uL, 0.5 mmol) and heated to 110 °C overnight. The reaction mixture was then cooled and concentrated, partitioned between H₂O and EtOAc and the mixture was extracted with EtOAc. The organic layers were combined, washed with H₂O and brine, dried (MgSO₄), filtered and the filtrate was concentrated to give a solid which was triturated with EtOAc to provide the title compound as a tan solid. MS (ES+) *m/e* 563 [M+H]⁺.

Example 24

***N*-(3-{{2-(4-amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl}oxy}phenyl)-6-{{2-(4-morpholinyl)ethyl}oxy}-3-pyridinecarboxamide**



Step 1. 6-Oxo-1,6-dihydro-3-pyridinecarbonyl chloride

4-Hydroxynicotinic acid (2.09 g, 15 mmol) was heated to 80 °C in CH₃CN (10 mL) and pyridine (6 uL, 0.075 mmol). Thionyl chloride (1.15 mL, 15.8 mmol) was added dropwise with caution and heating was continued for 30 min after the

final addition. The reaction mixture was cooled and the precipitate which formed as filtered, washed with cold CH₃CN and dried to give the title compound as a tan solid (1.6 g, 68%).

5 **Step 2. *N*-(3-{[2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-6-oxo-1,6-dihydro-3-pyridinecarboxamide**

The product of Step 1 (93 mg, 0.6 mmol) was added to a solution of the product of Example 3 (200 mg, 0.6 mmol) in pyridine (1 mL) and the resulting mixture was allowed to stir at rt for 30 min. The solution was poured into H₂O and
10 the precipitate which formed as filtered, washed with H₂O and Et₂O and dried to give the title compound as a tan solid (150 mg, 55%). MS (ES+) *m/e* 459 [M+H]⁺.

Step 3. *N*-(3-{[2-(4-Amino-furazan-3-yl)-1-ethyl-1*H*-imidazo[4,5-*c*]pyridin-6-yl]oxy}phenyl)-6-{[2-(4-morpholinyl)ethyl]oxy}-3-pyridinecarboxamide

15 2-Chloroethylmorpholine hydrochloride (104 mg, 0.6 mmol) was added to a slurry of the product of Step 2 (135 mg, 0.3 mmol) and powdered K₂CO₃ (1g) in DMF (2 mL) and the mixture was heated to 80 °C for 3h. The mixture was cooled, diluted with H₂O and extracted with EtOAc. The combined organic extracts were washed with H₂O and brine, dried (MgSO₄), filtered and the filtrate was concentrated
20 to give a yellow oil which was purified by reverse phase HPLC to give the title compound (50 mg, 30%). ¹H NMR (400 MHz, CD₃OD) δ ppm 9.13 (s, 1H), 8.69 (s, 1H), 8.09 (d, *J* = 9.3, 1H), 7.92 (s, 1H), 7.69 (d, *J* = 8.0, 1H), 7.60-7.53 (m, 2H), 7.12 (d, *J* = 8.0, 1H), 6.67 (d, *J* = 9.4, 1H), 4.76 (br q, 2H), 4.53 (br m, 2H), 3.83-3.70 (m, 8H), 3.33 (m, 2H), 1.46 (br t, 3H). MS (ES+) *m/e* 572 [M+H]⁺.

25

ROCK kinase assay:

ROCK inhibitor activity was determined using human recombinant ROCK1 kinase domain (amino acid 2-543) expressed in Sf9 cells (see WO9967283). The enzyme was purified using His-tag NTA column and Source15 HPLC
30 chromatography. The assay of Rock-1 activity involved incubation with peptide

substrate and ATP³³, the subsequent incorporation of P³³ into the peptide was quantified by Scintillation Proximity Assay (SPA - Amersham Pharmacia).

For IC₅₀ determination, test compounds were typically dissolved at 10mM in 100% DMSO, with subsequent serial dilution in 100% DMSO. Compounds were typically assayed over an eleven-point dilution range with a concentration in the
5 assay of 50uM to 0.8nM, in 3-fold dilutions. IC₅₀ values were calculated by bespoke curve fitting software and then converted to pIC₅₀.

Assays were performed in opaque, white walled, 384 well plates, in a total assay volume of 20ul. The assays contained: 1nM hROCK1; 1uM biotinylated
10 peptide (biotin-Ahx-AKRRRLSSLRA-CONH₂); 1uM ATP; 1.85kBq per well ATP(α -³³P); 25mM Hepes pH 7.4; 15mM MgCl₂; 0.015% BSA. The reactions were incubated at 22°C for 120 minutes, then terminated by the addition of a 50ul solution containing 60mM EDTA and streptavidin PVT SPA beads. The SPA beads were added to a concentration of 0.14mg per well. The plates were allowed to
15 incubate at 22°C for 10 minutes before centrifugation at 1500 rpm for 1 minute. P³³ incorporation was quantified by scintillation counting in a Packard TopCount.

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by
20 reference herein as though fully set forth.

The above description fully discloses the invention including preferred embodiments thereof. Modifications and improvements of the embodiments specifically disclosed herein are within the scope of the following claims. Without further elaboration, it is believed that one skilled in the art can, using the preceding
25 description, utilize the present invention to its fullest extent. Therefore the Examples herein are to be construed as merely illustrative and not a limitation of the scope of the present invention in any way. The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows.